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The chemokine receptor CCR5 has been implicated in the pathogenesis of cancers and 
AIDS. A series of novel piperidine derivatives were designed, synthesized, and evaluated as 
CCR5 antagonists. The ability of the new ligands to inhibit the increment of intracellular calcium 
level stimulated by endogenous ligand CCL5 was measured in the calcium mobilization assay as 
an indication of its CCR5 receptor antagonism. The anti-proliferation assay was performed to 
measure the ability of these new compounds to inhibit the proliferation of prostate cancer cell 
lines, PC-3 and M12. A new lead compound has been identified which showed micromolar level 





beginning of a thorough analysis of the CCR5 receptor antagonist binding pocket in the CCR5 
receptor. Further examination may help identify next generation lead to develop highly selective 










1. General Introduction 
1.1 Inflammation and cancer: 
       Inflammation is a fundamental physiologic process that is necessary for wound 
repair and recovery from infection.1 This process acts as a defense mechanism helping the 
host fight against infections. However, inflammation is a self-limiting process.2 
Uncontrolled or abnormal regulation of this process can lead to carcinogenesis.1 As early 
as the 19th century, Rudolf Virchow noticed leucocytes in neoplastic tissue and made a 
connection between inflammation and cancer.3 Currently it has been reported that 25% of 
the cancers worldwide are caused due to infectious agents or an inflammatory condition.2 
For example; papillomavirus serves as the inflammatory stimuli in cervical cancer. A 
similar analogy can be drawn between hepatocellular carcinoma and hepatitis virus (B and 
C), gastric cancer and H. pylori, and colorectal cancer and inflammatory bowel disease.3 
The main purpose of an inflammatory response is to create a tissue 
microenvironment. The microenvironment recognizes foreign particles and repairs cellular 
damage thus, leading to eradication of the foreign particles and infected cells.6 The 
environment is rich in inflammatory cells which is an integral part of the neoplastic 
process, leading to proliferation, migration, and survival of cells.5 
Under homeostatic conditions, when tissues are either exposed to some chemical 
irritant or wounded, inflammatory cells remove these wounded and damaged cells. This is 
done by induction of cell death or phagocytosis. The inflammatory cells also promote cell 
growth and proliferation to facilitate tissue regeneration and wound healing. The process 
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of proliferation and inflammation subsides once the chemical irritant or inflammatory 
stimulus is removed, and the wound is repaired. Chronic inflammation brings about 
alterations in the normally growing cells by affecting oncogenes leading to continued and 
sustained proliferation of the cells. This causes the uncontrolled growth of cells which 
eventually leads to neoplasm.5 
1.2 Tumor Microenvironment:  
In 1889, Stephen Paget emphasized the importance of the tumor microenvironment 
in tumor growth and progression. The “seed and soil” hypothesis was postulated by him. 
This hypothesis stated that factors in the tumor microenvironment constitute the fertile soil 
which promotes the growth and metastasis of cancer. This hypothesis has been validated 
and continues to hold true in associating the ability of the tumor cell (seed) to metastasize 
successfully to the microenvironment (soil).7  
The tumor microenvironment comprises of two major components. These include 
the cellular and the humoral components. The cellular components include macrophages, 
dendritic cells, lymphocytes and leucocytes. The humoral components include cytokines 
and chemokines.6 Tumors, their stromal areas, and precancerous tissues have a large and 
diverse population of the cellular and humoral components thus, contributing in cancer 
initiation, promotion and metastasis.5 
1.2.1 Cellular components: 
  Macrophages are the major component of the tumor microenvironment.3 They are 
also known as tumor-associated macrophages (TAM).4 They are differentiated monocytes 
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that mainly originate from the bone marrow. Macrophages in the body are in continuous 
search of foreign antigens which are phagocytosed and processed.8 Due to this function, 
TAMs are recruited to sites of tissue injury and inflammation.4 Under homeostatic 
conditions, macrophages are appropriately activated. Upon activation, TAMs have the 
ability to kill tumor cells and cause tissue destruction. However, TAMs can also produce 
angiogenic and growth factors which stimulates tumor-cell proliferation and angiogenesis. 
They also produce protease enzymes which can degrade the extracellular matrix and 
hence, favor invasion and metastasis.3 The major pro-tumoral function of TAM is the 
suppression of anti-tumor immune response.9  
There are two types of macrophages: M1 and M2 macrophages. M1 macrophages 
are anti-tumor in function. They perform tumor surveillance functions. TAMs are M2 type 
of macrophages which contributes to the immuno suppressive tumor microenvironment. 
These macrophages show several pro-tumoral functions such as angiogenesis, matrix 
remodeling and suppression of adaptive immunity. When the macrophages are recruited 
into the tumor microenvironment, they are exposed to very high levels of inflammatory 
cytokines. This selectively leads to activation of the M2 subtype of macrophages which 
are pro-tumor in function.8  
Dendritic cells, also known as tumor-associated dendritic cells (TADC) are another 
important component of the tumor microenvironment. They maintain both innate and 
adaptive immunity by activating antigen specific immunity and maintaining tolerance.9 
Dendritic cells are the first cells to migrate to the tumor site for recognizing the tumor 
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cells and inducing anti-tumor immunity. There are two forms of dendritic cells present in 
humans which are dendritic cells 1 and dendritic cells 2. They are myeloid and lymphoid 
lineage pathways respectively, which differentiate from hematopoietic progenitor cells 
under the control of complex network of cytokines and chemokines. Dendritic cells 1 
originates in the bone marrow as immature dendritic cells.8 TADC with an immature 
phenotype are defective in stimulating T cells. The immature TADC are usually present in 
the tumor mass.9 They mature once they process foreign antigens which are brought about 
by inflammatory signals.8 Mature TADC are present in the peri tumoral area.9 Cancer cells 
are active in attracting immature dendritic cells which are accumulated with in the tumor. 
As a result of this, tumor cells contain an abundant amount of immature dendritic cells, 
which are unable to exert their function of antigen presenting although they can take up 
antigens.8                                    
1.2.2 Humoral components: 
The humoral components of the tumor microenvironment include cytokines and 
chemokines predominantly. Cytokines are a large group of polypeptides which are 
secreted by living cells. They regulate cellular functions such as immune cell activity, and 
proliferation and differentiation of a wide variety of cell types. Interleukins (IL), tumor 
necrosis factor (TNF) and chemokines are the cytokines which are an integral part of the 
inflammatory process.10 
Cytokines produced by leucocytes which affect other leucocytes are termed as 
interleukins. Interleukins stimulate the proliferation and differentiation of T and B 
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lymphocytes as well as other cells involved in the immune response.10 Malignant cells 
secrete cytokines like interleukin-1 (IL-1) and interleukin-6 (IL-6) which promotes tumor 
cell growth and resistance to therapy.3 
One of the major mediators of inflammation is tumor necrosis factor. They 
perform actions which mediate both tissue destruction as well as recovery. It stimulates 
fibroblast growth at the site of inflammation and thus, induces cell death of mutated and 
diseased cells. Anti-tumor activities like destruction of tumor associated blood vessels are 
performed by TNF at malignant sites. However, when they are chronically produced, they 
perform pro-tumor functions. This contributes in tissue remodeling and stromal 
development which is necessary for tumor growth and metastasis. TNF is often detected in 
breast, ovarian, prostate, colorectal, and bladder cancer.3 
Besides the cellular and humoral components, a number of other factors are 
present in the tumor microenvironment with potentiates cancer progression. Reactive 
oxygen species (ROS) and reactive nitrogen species (RNS) are produced in inflamed 
tissues. They attack the invading infectious agents and other foreign bodies by oxidation, 
nitration, and other reactions. Excessive production of these reactive species can cause 
DNA damage and mutations, and injure the host cells leading to neoplasm.5 The tumor 
microenvironment is also made up of extracellular matrix and stromal cells. The stromal 
cells include fibroblasts and vascular cells. There is a specific stromal fibroblast fraction 
known as carcinoma-associated fibroblasts (CAFs). CAF has striking tumor-promoting 
properties. CAFs were found to exhibit increased levels of chemokines which recruits 
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endothelial progenitor cells (EPCs) into the tumor mass, thus favoring and supporting 
tumor angiogenesis. In vivo, the CAF’s can promote tumor progression.8  
The various components in the tumor microenvironment are recruited to the sites 
of inflammation by a process known as chemotaxis. Chemotaxis is a phenomenon in 
which the migrating cell’s direction is determined by the concentration gradient of 
extracellular chemicals. Chemotaxis plays an important role in many diverse physiological 
processes like recruitment of leucocytes to the sites of infection and trafficking of 
lymphocytes. A number of molecular components are involved in chemotaxis. For 
example, leucocyte migration is guided by a set of short peptides known as chemokines.11 
1.3 Chemokines: 
Chemokines are chemo attractant cytokines. They were initially characterized 
because of their association with inflammatory responses by stimulation of leucocyte 
chemotaxis during inflammation. These small proteins activate G-protein-coupled 
receptors (GPCRs) and thereby induce cells to migrate in a concentration gradient. They 
are a family of small proteins typically defined by four cysteine residues. The first 
cysteine forms a disulfide bond with the third cysteine residue and the second cysteine 
residue in the sequence forms a disulfide bond with the fourth cysteine residue. The family 
of chemokines comprises over 40 members.12, 13 Typical chemokines can be found easily 
in genome sequences owing to their relatively small size. Each of them is made up of 70-
90 amino acids.11  
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Chemokines are sub-classified into four classes based on the location of the first 
two cysteine residues in the molecule. Those chemokine which have an intervening amino 
acid between the first two cysteine residues are termed as CXC or α-chemokines.13 There 
are 17 members in this family of chemokines.14 The CC chemokines or the β-chemokines 
are those which have no intervening amino acid. In other words, the first two cysteine 
residues are adjacent to each other. A few chemokines from this family have six cysteine 
residues instead of four. All of them are disulfide bonded to each other.13 28 members so 
far have been identified in this family.14 The third sub-family is the CX3C or the γ-
chemokine family. There are three intervening amino acids between the first two cysteine 
residues. Presently, only one protein has been identified in this family. The CX3C 
chemokine is unusual because it is a part of a cell surface receptor. The last sub class is the 
C or γ-chemokine. This class is an exception to the four-cysteine paradigm and has only 
two cysteine residues.13 XCL1 and XCL2 are examples of chemokines belonging to this 
class which lack two out of the four cysteine residues.14 
Chemokines can also be classified according to their functional properties. 
Inducible (inflammatory) and constitutive (homeostatic) chemokines are the two classes. 
Inducible chemokines are induced by inflammatory stimuli. Thus, they control the 
recruitment of leucocytes into inflamed and injured tissue. Constitutively expressed 
chemokines perform various housekeeping functions.8 
The CXC family of chemokines can be further classified based on the existence of 
glutamate-leucine-arginine (E-L-R) motif which is located upstream from the CXC 
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sequence. They are classified into ELR+ and ELR- chemokines which stand for ELR 
positive and ELR negative respectively. This motif is important as the NH2 terminal of the 
chemokines is responsible for attracting inflammatory cells. This motif is also necessary 
for eliciting the angiogenic properties of the chemokines. CXCL1, CXCL2, CXCL3, 
CXCL5, CXCL6, CXCL7 and CXCL8 are examples for ELR+ chemokines. ELR- 
chemokines usually have angiostatic and anti-invasive properties. Examples of such 
chemokines are CXCL4, CXCL4L1, CXCL9, CXCL10, CXCL11 and CXCL14. There is 
an exception to the class of ELR- chemokines. CXCL12 is an ELR- chemokine which 
possesses angiogenic properties.14 
Chemokines can form dimers or other high order structures at chemokine rich sites 
like the sites of inflammation. Such chemokines have synergism, thus, strongly enhancing 
leucocyte migration and activation.8 Due to the similarity between the processes of cancer 
invasion and metastasis, and entry of leucocytes into inflamed tissue, cancer biologists 
postulated that tumor cells may use chemokine mediated mechanisms during the process 
of metastasis.8 Chemokines exert their functions by interacting with cell surface receptors 
known as chemokine receptors. 
1.4 Chemokine Receptors:  
Chemokine receptors are members of a large super family of cell membrane 
receptors called G protein coupled receptors. They have seven trans-membrane spanning 
helices. Chemokines function by activating the chemokine receptors.15 Twenty chemokine 
receptors have been identified to date.12 These receptors are embedded in the cell surface 
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lipid bilayer. The chemokine receptors have been designated as CXCR1 through 6, CCR1 
through 11, XCR1 and CX3CR1. This nomenclature is given to them based on the type of 
chemokines they bind. CXCR1 through 6, CCR1 through 11, XCR1 and CX3CR1 bind to 
CXC, CC, C and CX3C chemokines sub family respectively.13  
All these receptors contain around 350 amino acids each and have a molecular 
weight of about 40 kDa. Most of the chemokine receptors initiate ligand induced signaling 
cascades by receptor dimerization.8 They form homo dimers and occasionally hetero 
dimers.12 Unlike other GPCRs, chemokines and their receptors have over lapping 
specificities for each other.11 There are multiple ligands for a single receptor and vice-
versa. For example, the CXCR2 has 8 different CXC chemokines which can bind to it. In 
a case where CXCR2 is defective, CXCL8 and CXCL5 still exert their actions via another 
CXCR receptor, CXCR1.8 However; receptors interacting with multiple chemokines are 
capable of doing so with chemokines belonging to the same sub family. Binding of 
chemokines across sub families is rare.13 
Infiltrating leucocytes are not the only cells that respond to chemokine gradients. 
Cancer cells themselves express chemokine receptors and respond to chemokine 
gradient.16 Around 23 different types of human cancers express the chemokine receptor 
CXCR4. However not all cancer cells in the primary tumor express CXCR4. For instance, 
in ovarian and lung cancer only a small population of cells expresses the CXCR4 receptor. 
The expression of CXCR4 is low or absent in normal breast and lung cancer cells. 
Therefore, its expression is characteristic of malignancy.16   
    10 
 
Organ specific metastasis is governed by interaction between chemokine receptors 
and chemokine gradients in target organs.16 This can be explained with an example of a 
comprehensive survey of chemokines and their receptors in breast cancer patients 
performed by Muller and co-workers. It was found that the chemokine receptor CXCR4 
was expressed more in breast cancer tissue than normal breast tissue. The endogenous 
ligand CXCL12 was expressed in many organs such as lymph nodes, bone marrow and 
lungs. These were the organs where breast cancer metastasized.8  
Over expression of CXCR4 on neoplastic cells assists the cancer cells in adhering 
to the vascular endothelium in distant tissues. This is one of the first steps in establishing a 
metastatic niche. Various growth factors such as vascular endothelial growth factor 
(VEGF), epidermal growth factor (EGF) and inflammatory cytokines such as tumor 
necrosis factor-α (TNF-α), interferon-γ have also been found to correlate to chemokine 
receptor expression in cancer.8  
Chemokine receptors function as allosteric molecular relays. When chemokine 
binds to the receptor, the tertiary structure of the receptor is modified.14 This activates the 
hetero trimeric G proteins. This activation causes activation of a signaling network leading 
to chemotaxis.11 It was initially assumed that chemokine receptor function is governed 
entirely by Gi –mediated processes. This was further confirmed as it was found that the 
chemokine functions are blocked in cells pre-treated with pertussis toxin.17 However, 
recent evidence suggests that chemokines function through other G protein subtypes as 
well as non-G-protein mediated pathways.18  
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When the chemokine binds to the extracellular part of the receptor; the receptor is 
stabilized in a conformation such that the hetero trimeric G-protein is activated (Figure 1). 
G-protein is present in the intracellular part. The G protein has three subunits: α, β, γ. The 
Gα subunit is tightly associated with the β subunit, which in turn is in tight association 
with the γ subunit. The Gα subunit interacts with the intracellular loops two and three, as 
well as the C terminal domain. Intracellular loop two has the important DRY motif which 
is essential for interaction with the Gα subunit. GDP is bound to Gα in the inactive state of 
the receptor. When an agonist binds, GDP is replaced by GTP. The Gα-GTP subunit and 
the Gβγ subunit dissociate from each other as well as the receptor, and subsequently 
activate a number of signaling pathways downstream.18 Adenylyl cyclase is the only 
effector known to be regulated directly by Gα subunit.19 The βγ subunit causes transient 
accumulation of phosphatidylinositol-3,4,5-triphosphate (PIP3). This is coupled to the 
activation of proteins containing PIP3 binding motifs.12  
If there is continued stimulation of the receptor by the chemokine, receptor 
desensitization and internalization occurs. This process occurs by phosphorylation of 
certain residues in the C-terminal domain of the receptor by G-protein receptor kinases 
(GRK). Receptor phosphorylation stimulates the binding of arrestins which acts as a steric 
block thus, preventing the further interaction of the receptor. This eventually leads to 
receptor desensitization and internalization (Figure 1).18, 20 
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Decoy receptors are types of chemokine receptors that negatively regulate the 
immune and inflammatory response.12 DARC, D6 and CCX-CKR are three decoy 
receptors that have been identified. DARC is expressed by erythrocytes and vascular 
endothelial cells. This receptor is up regulated during inflammation. It binds pro 
inflammatory chemokines belonging to the CC and CXC sub class. This receptor lacks the 
intracellular signaling motifs, and hence, it does not support ligand induced signaling and 
migration. It neutralizes chemokines at extracellular barriers. Humans who lack the 
erythroid DARC may contribute to the increased progression and mortality of prostate 
cancer. Almost all inflammatory CC chemokines binds to the D6 receptor. This receptor 
undergoes rapid internalization. This leads to degradation of the ligand, however the 
receptor recycles back. Similar to DARC and D6 receptors, the CCX-CKR receptor lacks 
signaling motifs.14 
 A chemokine receptor of considerable interest to researchers is the CC chemokine 
receptor CCR5. CCR5 has been widely studied owing to its implication in various disease 
states. It has been found that prostate and breast cancer tissues express the CCR5 receptor. 
CCR5 is also expressed on human CD4+ T cells and hence, is a critical mediator in the 
human immune deficiency virus (HIV) entry into the host cell. Thus, due to its diversity, 
the CCR5 receptor serves as an important therapeutic target.  
1.5 CCR5: 
The CC chemokine receptor 5 (CCR5) was first identified in 1996.21 It is a seven 
trans-membrane, G-protein-coupled receptor. CCR5 has 352 amino acids with a mass of 
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about 40.6 kDa. It shares 71% sequence identity with CCR2. Most of the differences are 
located in the extracellular and cytoplasmic domains. It has four cysteine residues in the 
extracellular domains as well as a conserved DRYLAVHA sequence which is important 
for interaction with the G protein (Figure 2).22-24 Macrophage inflammatory protein 1α 
(MIP-1α, CCL3), MIP-1β (CCL4) and regulated on activation, normal T cell expressed 
and secreted (RANTES, CCL5) are the endogenous chemokine agonists that bind to 
CCR5.21 Also, monocyte chemo attractant protein 2 (MCP-2, CCL8) and MCP-4 (CCL13) 
show reasonable activity at CCR5.25 
CCR5 receptor activation involves two steps. This includes an initial interaction 
between the chemokine and amino terminal domain of the receptor as well as the 
adjoining extra cellular loops. This is followed by interaction of the amino terminal with 
the trans-membrane domain which leads to receptor activation.22 Like other chemokine 
receptors, CCR5 binds to inhibitory Gi/o guanine nucleotide binding protein thus inhibiting 
3’-5’-cyclic adenosine monophosphate production (cAMP) by inhibiting adenylyl cyclase. 
They also stimulate the release of intracellular Ca2+. Effects on adenylyl cyclase are 
mediated via G protein α subunits whereas effects on Ca2+ mobilization occur due to 
signaling mediated by the βγ subunit. Treatment with pertusis toxin inhibits [35S]GTPγS 
binding which is stimulated by CCL3, CCL4, CCL5 and CCL8. It can also partially 
inhibit internalization of the receptor which is induced by the chemokines. These two 
features indicate that CCR5 function through Gi/o proteins.
26 
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Phospholipase C (PLC) is activated via CCR5 which results in the production of 
diacyl glycerol (DAG). This subsequently leads to the activation of protein kinase C 
(PKC). It mediates receptor regulation by receptor phosphorylation which is carried out by 
a class of serine threonine protein kinases know as G protein receptor kinases (GRK). This 
leads to receptor desensitization. The CCR5 ligands mainly activate three main members 
of the MAP (mitogen activated protein) kinase family. These include ERK1/2 
(extracellular signal-regulated kinase), p38 and SAPK/JNK which are critical for T cell 
proliferation and transcriptional activation of cytokine genes.27 
The chemokine receptor CCR5 serves as a portal of cellular entry for the human 
immunodeficiency viruses (HIV-1 and HIV-2). CCR5 and CXCR4 act as co receptors 
along with CD4 in vivo for the attachment and entry of HIV into the host cell.26, 27 Also, 
studies have shown that the chemokine CCL5 which is a potent chemotactic factor for 
inflammatory cells is important in the progression of breast cancer. The chemokine CCL5 
and its receptor CCR5 are over expressed in human prostate cancer cell lines.28 This 
makes the chemokine receptor CCR5 attractive as a therapeutic target.
17 
2.  Disease Involvement of CCR5 
The chemokine receptor CCR5 is implicated in various disease conditions. Some 
of these include Alzheimer’s disease, atherosclerosis, and cardiovascular diseases. 
However, its implication in cancer and acquired immune deficiency syndrome (AIDS) has 
been extensively studied by researchers. CCR5 receptor and its endogenous ligand CCL5 
(RANTES) are over expressed in cancer, specifically prostate and breast cancer. This 
receptor also serves as the co-receptor for the entry of Human immune deficiency virus 
(HIV) along with CD4 receptor and hence is involved in the pathogenesis of AIDS. The 
role and involvement of CCR5 in prostate cancer, breast cancer and AIDS are discussed 
below.  
2.1 Prostate Cancer: 
Prostate cancer is an extremely common malignancy of the male genitourinary 
tract.15 It is the most frequently diagnosed cancer and the second leading cause of cancer 
death among the men in the United States and Western Europe. The American Cancer 
Society estimates 240,890 new cases of prostate cancer and 33,720 deaths due to prostate 
cancer in 2011.29 North American men are at a higher risk of acquiring prostate cancer as 
compared to Asian men. This is due to a typical Western diet rich in saturated fats and 
little or devoid of fruits and vegetables which is most likely the culprit in the promotion of 
prostate cancer. Thus, diet and lifestyle are the important risk factors associated with 
prostate cancer. 30, 31 
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It has been widely known and accepted that there is a functional relationship 
between inflammation and cancer.3 Prostate cancer precursor lesions often show 
inflammatory infiltrates in close proximity. This has led scientists to consider 
inflammation in the etiology of prostate cancer.32 Several case studies have shown an 
association between prostate cancer and prostatitis, which is inflammation of the prostate 
gland.6 The anatomic position of the prostate gland is such that easy exposure to various 
infectious agents present in urine and sexual activity can lead to inflammation.33, 34  
Prostate specific antigen (PSA) is a membrane protein that is found predominantly 
in the epithelial cells of the prostate gland.35 This antigen is expressed in low levels in 
epithelial cells of the normal prostate gland in contrast to its high expression in metastatic, 
and androgen-insensitive prostate cancer. Thus, PSA is one of the most commonly used 
biomarker in the diagnosis and treatment of prostate cancer.36 However, biopsy of the 
prostate tissue is the only confirmatory diagnostic test for prostate cancer.15   
Many types of cancer cells including prostate cancer cells express chemokines and 
their receptors. It has been stated that chemokines and their receptors are involved in the 
growth and metastasis of prostate cancer.34 Vaday and co-workers performed a series of 
experiments to characterize the expression of CCL5 (RANTES) and its receptor CCR5 in 
prostate cancer cell lines. Four cell lines were used which were PC-3, LNCaP, DU145, 
and human prostatic adenocarcinoma cells (E-CA-65). MCF-7, which is human breast 
carcinoma cell line, was used as the positive control. It was seen that CCL5 was expressed 
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in all these cell lines with DU145 and LNCaP expressing the highest levels (Figure 3). 
PC-3 and E-CA-65 secreted low levels of CCL5.28  
CCL5 was capable of binding to three receptors; CCR1, CCR3 and CCR5 to exert 
its action. Anti-bodies were used against each of these three receptors to measure their cell 
surface expression in prostate cancer cell lines. The receptor CCR5 was expressed on the 
cell surface of all three prostate cancer cell lines PC-3, DU145 and LNCaP. Also, large 
amounts of intracellular CCR5 were seen in PC-3 cell lines. On examining the expression 
of receptors CCR1 and CCR3 in the three prostate cancer cell lines, it was found that large 
amounts were expressed in the intracellular pools. However, their cell surface expression 
was lower than the levels of CCR5 (Table 1). Thus, it could be concluded that the cell 
surface expression of CCR5 was greater than that of CCR1 and CCR3 in prostate cancer 
cell lines.28 
 The effect of CCL5 on the invasion and proliferation of cancer cells was studied. 
It was seen that CCL5 causes the migration of PC-3 and LNCaP cell lines. TAK-779 
which is an antagonist of the receptor CCR5 was used to assess CCL5 induced cell 
invasion and proliferation. It was noted that TAK-779 was capable of inhibiting CCL5 
induced invasion as well as proliferation of PC-3 and LNCaP cells (Figure 4).28 Thus, 
CCR5 antagonists can be used to prevent the cell proliferation, invasion and metastasis 
that occurs in prostate cancer.      
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Figure 3: Expression of CCL5 mRNA in prostate cancer cell lines 
 CCL5 (RANTES) expression was analyzed in prostate cancer cell lines PC-3, DU145, 
LNCaP and primary cultures of prostate adenocarcinoma. The positive control used was 
MCF-7 breast carcinoma cell line. Serum free conditioned media was collected after 24 
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Table 1: Total cell surface and intracellular expression of CCR1, CCR3 and CCR5 in PC-
3, LNCaP and DU145 cell lines. 
 
The data represents the percentage of positive cells in the total cell population. Cells were 
stained with anti-CCR1, anti-CCR3, and anti-CCR5 antibodies. Their fluorescence was 






 PC-3 L)CaP  DU 145 
CCR1 surface 0 22.6 16.6 
CCR1 total cellular 35.2 52.4 50.2 
CCR3 surface 6.1 29.5 8.0 
CCR3 surface 95.0 88.6 77.8 
CCR5 surface 28.8 48.3 38.8 
CCR5 total cellular 88.3 89.5 98.6 
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Figure 4: Inhibition of CCL5 (RANTES) mediated cell proliferation in DU 145 prostate 
cancer cell line by CCR5 antagonist TAK-779. 
DU 145 cells were exposed to either CCL5 alone in a concentration of 10 ng/ml or both 
CCL5 (ng/ml) and TAK-779 (10-500 nM). This was incubated for 24 hours followed by 
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2.1.1 CCR5+32:  
CCR5∆32 is a non-functional allele resulting from 32-bp deletion in CCR5 gene. 
This results in non-functional receptor. CCR5∆32 encodes a truncated protein that is not 
detected or present on the surface of the cell. This is due to 32 base pair deletion which 
causes a shift in the reading frame. There is creation of an early stop codon thus leading to 
the production of a truncated protein. This truncated protein is retained in the endoplasmic 
reticulum.37 CCR5∆32 is common among Centenarians. 
Ballitreri.C et al performed a study to evaluate whether CCR5∆32 deletion of the 
CCR5 gene may be associated with susceptibility to prostate cancer. This study consisted 
of 50 human prostate cancer tissues which were obtained from patients affected by 
prostate cancer. The DNA samples were genotyped for CCR5∆32 deletion. The control 
group consisted of Centenarians. Centenarians have no history of cancer or any other age 
related disease. This control group had previously been genotyped for CCR5∆32 deletion. 
On analyzing the data, it was found that the anti-inflammatory CCR5∆32 allele was under 
expressed in prostate cancer patients while CCR5∆32 deletion was over-expressed in 
Centenarians. This suggested that CCR5∆32 deletion is a resistance factor in the 
development of prostate cancer.38 
2.2 Breast Cancer: 
 
Carcinoma of the breast is the second leading cause of cancer related death among 
women in the United States.39 The American Cancer Society estimates about 232,620 new 
cases and 39,970 deaths due to breast cancer in 2011.29 Only modest improvements in 
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survival rates have been achieved despite advances in the diagnosis and treatment of 
breast cancer. Thus, there is a continuous search for new insights into the role of various 
cellular effectors in the progression of this disease.40  
The tumor microenvironment in breast cancer consists of various inflammatory 
mediators such as inflammatory cells, cytokines and chemokines.41 The chemokines are 
capable of promoting tumor growth.  They also play a prominent role in tumor cell 
migration which could lead to increased invasive and metastatic propensity.39 However; 
several chemokines are expressed by normal breast tissue even though they are expressed 
at low levels. For example, the chemokines CXCL1, 2, 3, 4, 5, 6, 7 and 8 have been 
detected in human milk. The normal breast tissue also secretes other cytokines like IL-6 
and TNF-α.14  
In breast cancer tissue, the chemokines CXCL12, CCL2, and CCL5 have been 
detected at high levels. These chemokines are expressed minimally by normal breast 
epithelial cells. This indicates that these chemokines are acquired in the course of 
transformation to malignancy. They are critical mediators and play an important role in 
the progression of the tumor.42 Along with chemokines; their receptors are also over 
expressed. The receptor CXCR4 is up regulated in breast cancer compared to normal 
breast tissue. Also, its ligand CXCL12 shows peak mRNA level expression in the 
metastatic sites of breast cancer. 14        
Youngs et al. performed a study to monitor the chemotactic response of MCF-7 
breast cancer cell lines to α and β chemokines. The MCF-7 cell line was obtained from a 
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pleural effusion of a 69 year old female with metastatic mammary carcinoma. It was noted 
that MCF-7 cells migrated in the presence of both α and β chemokines. However, the β 
chemokines elicited a greater chemotactic response. MIP-1α induced significant migration 
of MCF-7 cells in 5 out of 6 experiments. Similarly MIP-1β and RANTES (CCL5) 
induced migration in 5 out of 6 and 6 out of 6 experiments respectively.39       
RANTES (CCL5) expression is rarely observed in those patients with benign 
breast disorders. Advanced breast carcinoma patients over-express RANTES. In such 
patients, only the malignant epithelial cells expressed RANTES. Non-malignant benign 
lumps and mammary ducts that were in close proximity to the malignant epithelial cells 
rarely expressed RANTES. On evaluation of the RANTES expression in different 
pathological stages of breast cancer, it was found that higher expression was seen in 
patients with disease in stages II and III. About 83% patients in stage II and 83.3% 
patients in stage III expressed RANTES. On the other hand, only 55% patients who were 
in stage I of the disease were positive for RANTES expression.43 This indicated that 
RANTES was expressed more in the advanced and later stages of  breast cancer than the 
initial stages.  
Robinson et al. performed a study to obtain evidence if the action of an antagonist 
for the CCR5 receptor would inhibit the tumor promoting role of the chemokine CCL5 
(RANTES). Met-CCL5 was used as the antagonist.44 Escherichia Coli expressed 
RANTES in which the protein retains the initiating methionine residue. This was known 
as Met-CCL5. The retention of the initiating methionine residue renders it inactive as an 
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agonist despite being correctly folded. However, it shows antagonistic activity. It is 
capable of antagonizing the effects induced both by RANTES and MIP-1α.45  
The activity of Met-CCL5 was tested against 410.4 tumor cells. The mice were 
injected with an intra-peritoneal injection of Met-CCL5 daily. The volume of the tumor 
was measured at regular intervals. The tumors were excised and weighed after five weeks 
of growth. The tumor weights were significantly lower which showed that Met-CCL5 did 
slow down tumor growth. There was also a substantial decrease in the proportion of 
macrophages in those tumors which were treated with Met-CCL5.44 Thus, CCR5 
antagonists can be used to decrease the progression of breast cancer as well as 
significantly lower the leukocyte population within the tumor. 
2.3 HIV/AIDS:  
The retro virus, human immune deficiency virus-1 (HIV-1), causes the disease 
acquired immuno deficiency syndrome (AIDS). Almost 30 years ago, in 1981, AIDS was 
first identified in the United States of America. About 2.7 million people are infected with 
HIV each year and around 33 million people are living with AIDS. Women comprise 
about 50% of the population living with AIDS. This is mainly because women have 
limited or no freedom to insist condom use, or choose sexual situations in developing 
countries.34 
 A number of anti-retroviral agents are available. Highly active anti-retroviral 
therapy (HAART) is an extremely powerful treatment for AIDS which was introduced in 
the early 90s. This is defined as three or more drugs concomitantly administered to 
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achieve suppression of the virus.46, 47 Recent studies have shown that 90% of the patients 
respond well to HAART and survive for at least five years if the treatment is initiated 
early. The different classes of anti-retroviral agents which are used in HAART include the 
reverse transcriptase inhibitors, the protease inhibitors and the integrase inhibitors which 
target the viral proteins.48   
The chemokine receptor CCR5 was identified about a decade ago as one of the 
major co- receptor that was used by HIV to gain entry into cells.49 The viral envelope 
contains two glycoproteins, gp120 and gp41. The main receptor protein is CD4 and a co 
receptor which is a chemokine receptor. This co receptor is typically either CCR5 or 
CXCR4. The HIV-1 strains are classified into three major groups based on the co-receptor 
which they use for entering into the host cell. They could either be R5 (CCR5-tropic), X4 
(CXCR4-tropic) and R5/X4 (they are able to use either CCR5 or CXCR4).50 
A number of steps are involved in the entry of HIV into the host cell which is 
shown in Figure 5. Complex interaction between the glycoproteins present in the viral 
envelope and the host cell surface receptors (CD4 and CCR5 or CXCR4) is the initial step. 
This involves binding of the glycoprotein gp120 to the host cell surface receptor CD4. 
This brings about a conformational change in the viral gp120 thus creating or exposing a 
binding site for the chemokine receptor. Once gp120 binds to the chemo kine receptor, 
another conformational change is induced which allows the viral glycoprotein gp41 to 
initiate fusion. The gp41 glycoprotein contains two alpha-helices that form a hairpin 
configuration. A hydrophobic fusion peptide is inserted into the cell membrane of the host. 
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This leads to spanning of gp41 between the virus and host cell membrane. The helices of 
gp120 then folds into a six helix bundle. This brings the N terminal and the C terminal 
close eventually bringing the viral and cell membranes close. This proximity leads to 
contact between them thus allowing mixing.50, 51 
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The CC chemokines RANTES, MIP-1α, and MIP-1β suppress infection caused by 
R5 tropic HIV. It was demonstrated that these chemokines sterically block the site where 
the viral envelope interacts with the receptor. This is the proposed mechanism of 
inhibition which leads to receptor down modulation. SDF-1, which is the endogenous 
ligand for the receptor CXCR4, leads to down regulation of CXCR4 thereby blocking 
infection caused by X4 tropic HIV. This ability of chemokines to inhibit HIV-1 infection 
made these molecules attractive targets for the development of anti-HIV therapeutic 
agents.46, 52  
CCR5 antagonists can thus be successfully used as anti-retroviral drugs in 
therapeutics. Maraviroc was the first and only CCR5 antagonist approved for use in both 
treatment-experienced and treatment naïve patients.37 CCR5 antagonists are allosteric and 
non-competitive inhibitors of the receptor. They bind to the receptor thus inhibiting the 
interaction between gp120 and the co-receptor.53 However, there is a limitation in treating 
AIDS patients with CCR5 antagonists. It would be ineffective in patients where HIV uses 
CXCR4 as the co- receptor.37 On the other hand, only advanced stages of the disease use 
CXCR4 as the co-receptor. HIV-1 strains use CCR5 as the co-receptor in the early stages 
of the disease. Thus, CCR5 antagonists can prevent the progression of AIDS.37 
A naturally occurring 32-bp deletion in the human CCR5 gene is known as 
CCR5∆32. Individuals who carry two alleles of this CCR5∆32 mutation (CCR5-/-) are 
those who are highly protected against infection by HIV-1. Those who are heterozygous 
for this mutant allele (CCR5+/-) are not protected against infection. However, such 
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individuals have a delayed progression of the disease. This indicates that a partial 
resistance can occur if there is a single copy of CCR5∆32. In very rare cases, people 
homozygous for CCR5∆32 allele showed HIV infection. The mechanism of infection in 
such cases has not been identified. Exclusive use of CXCR4 by the virus could probably 
be the reason.50, 54 
Thus, the CC chemokine receptor CCR5 has been implicated in the progression of 
various human cancers like the prostate and breast cancer. It is also an important co-
receptor which mediates the entry of the HIV virus into the host cell. Therefore, CCR5 
antagonists could prevent the entry of the HIV into the host cell by blocking the receptor. 
These antagonists can also be used as anti-proliferative agents in prostate and breast 
cancer. Detailed study of the CCR5 antagonists previously synthesized will help in better 
understanding of the CCR5 as a therapeutic target. 
32 
3. CCR5 Antagonists 
Highly active anti-retroviral therapy (HAART) has significantly affected the 
treatment and epidemiology of HIV-1 infection. Since 1989, HAART has successfully 
contributed in saving around 3 million years of life in the United States. However, the rate 
of resistance in patients infected with HIV-1 has drastically increased.69 A new and 
attractive strategy for treating HIV-1 infection is inhibition of viral entry into the host cell. 
Since the chemokine receptor CCR5 serves as a co-receptor for the entry of the virus into 
the host cell, targeting this receptor could serve as a new therapeutic approach in treating 
AIDS. Thus, identifying CCR5 receptor antagonists, which inhibits the binding and entry 
of HIV-1 into the host cell, would serve as a novel approach in the treatment of AIDS.70  
The CCR5 receptor is also implicated in cancer, specifically prostate and breast 
cancer with an inflammation etiology. The endogenous ligand CCL5 (RANTES) and 
CCR5 are over expressed in prostate and breast cancer. This may lead to proliferation, 
invasion and metastasis of tumor cells.43, 71 CCR5 receptor antagonists which can inhibit 
the binding of the endogenous ligand to the receptor may inhibit the proliferation and 
growth of tumor cells. Thus, the chemokine receptor CCR5 has been of interest to 
researchers due to its implication in various disease states. CCR5 antagonists would thus 
serve as a novel therapeutic approach in the treatment of several disease conditions.43   
A number of pharmaceutical companies conducted high throughput screenings of 
their in-house compounds in search of small molecule CCR5 antagonists. Compound 1 
was obtained as the initial lead from high throughput screening. This quaternary 
ammonium salt was optimized chemically which led to the discovery of TAK-779 (2).56 
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TAK-779 (2) was the first small molecule CCR5 antagonist that was reported in 1999 by 
Takeda chemicals, Japan (Figure 6).55 






                                                
                            1                                                                              2 
Figure 6: Initial lead (1) and TAK-779 (2) 
Radiolabelled ligand, [125I]-RANTES, binds to CHO-CCR5 cell (Chinese hamster 
ovary cell expressing CCR5) with a high affinity (Kd = 0.45 nM).  TAK-779 was able to 
inhibit the binding of [125I]-RANTES to CCR5 expressing CHO cells with an IC50 of 1.4 
nM. TAK-779 was a selective antagonist for the CCR5 receptor as it did not inhibit the 
binding of ligand to other chemokines receptors expressed by CHO cells namely, CCR1, 
CCR3, and CCR4. However, this potent and selective CCR5 antagonist was not developed 
further due to poor oral bioavailability and toxicity at the site of injection.56, 58 
Due to its drawbacks, the structure of TAK-779 was further modified. This 
included replacement of the quaternary ammonium moiety with a sulfoxide group, ring 
expansion to (6,8) fused nuclei, and replacement of the methyl group with 4-(2-
butoxyethoxy) group. This resulted in TAK-652 (3) which had increased potency and 
bioavailability (Figure 7).59 It inhibited the binding of [125I]-RANTES to CCR5 
expressing CHO cells with an IC50 of 3.1 nM. TAK-652 was also active against R5 HIV-1 
strains with an EC50 of 0.061 nM and EC90 of 0.25 nM. A single dose Phase I study for 
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TAK-652 has been completed.57 Administration of this drug up to 100 mg once a day was 
safe and well tolerated in humans. However, the clinical efficacy of TAK-652 in HIV-1 
infected individuals and further clinical data are awaited. It is currently being studied in 
Phase II clinical trials.72 
 
Figure 7: TAK-652 
Ono pharmaceuticals in collaboration with GlaxoSmithKline developed 
spirodiketopiperazine derivatives as CCR5 antagonists. ONO-4128/Aplaviroc (4), a highly 
potent CCR5 antagonist was developed by Ono pharmaceuticals (Figure 8).  This 
antagonist inhibited the replication of R5 viruses with an IC50 of 30-60 nM. Aplaviroc was 
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Figure 8: Aplaviroc/ONO-4128 
In early clinical studies, a dose of 600 mg of Aplaviroc twice a day for ten days 
was well tolerated and demonstrated reduction in viral load. However, three subjects 
developed hepatotoxicity in Phase II-b clinical trial. Also, in phase III clinical trial, one 
patient in a group of 44 patients developed idiosyncratic hepatotoxicity. Thus, the clinical 
studies of Aplaviroc were discontinued.72 
Schering-Plough developed two series of CCR5 antagonists: piperidino–piperidine 
and piperazino-piperidine. The initial lead (4) for the piperidino-piperidine series had 
moderate affinity for both the CCR5 (Ki = 64 nM) and M2 muscarinic receptor (Ki = 230 
nM). Medicinal chemistry optimization of compound 4 afforded compound 5; which had a 
Ki of 66 nM for the CCR5 receptor and Ki of 1323 nM for the M2 muscarinic receptor 
(Figure 9).58, 61, 62  
 
           
4                                                                            5 
Figure 9: Initial leads developed by Schering-Plough. 
SCH-C/SCH351125 (6) was Schering-Plough’s first clinical candidate (Figure 
10). This antagonist was developed by making certain structural changes to compound 5. 
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These included addition of an oxime at the benzylic position and replacement of 2,6-
dimethylbenzamide with 2,6-dimethylnicotinamide -oxide. SCH-C demonstrated 
excellent anti-viral properties with an IC50 of 3 to 78 nM against R5 tropic HIV-1 
isolates.61, 62 In clinical efficacy studies, a dose of 25 mg twice daily demonstrated a 
significant drop in viral load in ten out of twelve subjects. However, at the highest dose 
tested (400 mg), cardiac side effects were noted. Thus, further clinical efficacy studies of 












Figure 10: SCH-C / SCH351125 
Compound 7 (Figure 11), a potent antagonist for the M2 muscarinic receptor (Ki = 
0.8 nM), was the initial lead obtained in the piperazino-piperidine series of Schering-
Plough CCR5 antagonists. This compound had only moderate affinity for the CCR5 
receptor with a Ki of 440 nM. In an effort to improve affinity for the CCR5 receptor and 
reduce the affinity for the M2 muscarinic receptor, structural modifications were made to 
compound 7. Truncation of the left side and leaving a small para substituent on the phenyl 
ring afforded compound 8, which had high affinity for the CCR5 receptor (Ki = 20 nM) 
6 
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and reduced affinity for M2 muscarinic receptor. However, the major drawback of 8 was 
poor oral bioavailability in rat and hence, could not be developed further (Figure 11).58, 74 
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Figure 11: Initial leads in piperazino-piperidine series of Schering-Plough CCR5 
antagonists. 
SCH-D/Vicriviroc/SCH-417690 (9) developed later by Schering-Plough, was a 
potent CCR5 antagonist (Ki = 1.6 nM) (Figure 12). This compound was 2 to 40 times 
more potent than SCH-C against R5 HIV-1 isolates. Vicriviroc also demonstrated good 
oral bioavailibity in preclinical studies. In clinical studies, vicriviroc was well tolerated at 
a dose of 50 mg twice daily.59, 60 However, the Phase II clinical studies of vicriviroc were 
discontinued because there was a viral breakthrough in the group receiving this drug 
compared to the control group. This indicated that vicriviroc was not effective for use in 
treatment naïve patients. Phase II studies were then carried out in treatment-experienced 
patients. The results of this showed that vicriviroc exhibited strong antiviral activity, 
however five participants had an incidence of malignancy. Despite this, the study was 
continued as there was no causal association of the malignancy and vicriviroc. Phase III 
clinical trials were initiated in treatment experienced patients in late 2009.61, 62, 72 In 2010 
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Merck halted the phase III clinical studies of Vicriviroc in treatment-experienced patients 
due to no significant superior efficacy.84 
 
Figure 12: SCH-D/ Vicriviroc/ SCH-417690 
Acyclic and cyclic scaffold based CCR5 antagonists were developed by 
researchers at Merck. The initial lead (10) had an -methylbutane amine core with a 
spirocyclic piperidine moiety at the 4th position and a (S)-phenyl moiety at the second 
position. This compound had moderate affinity for the CCR5 receptor (IC50 = 40 nM). 
However, it demostrated very weak anti-viral activity and hence, compound 10 was 
further modified to afford compound 11 (Figure 13).58, 75, 76 
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Figure 13: Initial leads for Merck CCR5 antagonists. 
Compound 11 was an extremely potent CCR5 antagonist with an IC50 of 0.1 nM 
with good oral bioavailability in rats. The active conformation of this compound was 
locked in place with a 1,3,4-trisubstituted pyrrolidine to create a cyclic scaffold leading to 
compoud 12 which was an even more potent CCR5 antagonist with an  IC50 of 0.8 nM. 
The pyrrolidine scaffold in compound 12 gave rise to the cyclopentane template in 
compound 13, which was a potent CCR5 antagonist (IC50 = 1.1 nM). It demonstrated good 
anti-viral activity with an IC95 less than 8 nM (Figure 14). However, these CCR5 
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Figure 14: Cyclic CCR5 antagonists developed by Merck. 
Researchers at Pfizer developed piperidine-based CCR5 antagonists. The initial hit 
(14) identified from high throughput screening had good affinity for the CCR5 receptor 
(IC50 = 4 nM) despite the lack of anti-viral activity. Thus, the structure of 14 was modified 
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in an effort to improve the anti-viral activity. This led to tropane derived amide analogue 
(15) which showed excellent anti-viral activity (IC90 = 0.6 nM). However, due to 
unfavorable pharmacokinetic properties, 15  was subjected to further structural 
modifications (Figure 15).58, 59  
                  
14                                                                                                 15 
Figure 15: Initial leads for CCR5 antagonists developed by Pfizer. 
Structural modifications of 15 were made to afford compound 16. This compound 
demonstarted good anti-viral potency with an IC90 of 8 nM. A major drawback associated 
with this compound was cardiovascular side effects. It did not provide the desirable safety 
window and hence, could not be developed further. The cyclobutane moiety of compound 
16 was placed with a 4-substituted cyclohexane moiety. The compound 17 exhibited 
excellent anti-viral properties with an IC90 of 1 nM (Figure 16).
57, 58
 
The CCR5 antagonist (17) known as Maraviroc or UK-427,857, was capable of 
producing a reduction in the viral load on administering a dose of 25 mg once a day. This 
CCR5 antagonist was very well tolerated. The US Food and Drug administration advisory 
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panel approved the new drug on 24th April, 2007. On August 6, 2007 maraviroc received 
full FDA approval for use in treatment experienced patients.84  
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                 Figure 16: Pfizer CCR5 antagonists 
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4. Project Objectives and Design 
The chemokine receptor CCR5 in involved in the progression and development of 
a number of disease states like cancer and AIDS. Thus, targeting this receptor serves as a 
therapeutic approach. Since both CCL5 and CCR5 are over-expressed in cancer cells and 
tissues specifically prostate and breast cancer, CCR5 antagonists may prevent cancer 
progression and metastasis.  Also, due to the involvement of CCR5 as a co-receptor in the 
entry of HIV into the host cell, blocking this receptor with CCR5 antagonists may block 
the entry of the virus into host cell, thus preventing infection. 
 A number of pharmaceutical companies have developed CCR5 antagonists by 
conducting high throughput screenings. Barring Maraviroc, the remaining antagonists 
could not pass the clinical trial studies. Long-term toxicity and adverse events were the 
short comings of the CCR5 antagonists reported so far which necessitates the need for 
new drugs. Also, most of these antagonists interact with the transmembrane (TM) domains 
of the receptor. However, the extracellular loop 2 (EL-2) part of CCR5 interacts with 
gp120 for the virus to enter into the host cell.  
Based on these observations, the primary objective of this project was to 
synthesize small molecule CCR5 antagonists with structural features to interact with EL2 
of CCR5. A novel approach, molecular based drug design, was used by our lab to design 
and develop CCR5 antagonists. These CCR5 antagonists would serve as novel anti-cancer 
agents and entry inhibitors in HIV therapeutics.  
The background work, including molecular modeling studies, and the project 
design are discussed herein.  
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4.1 Background Work:  
Like most of the GPCRs, the crystal structure of CCR5 receptor has not been 
resolved. Thus, a homology model of the receptor was built based on the X-ray crystal 
structure of bovine rhodopsin.77 In order to characterize the binding site of the CCR5 
antagonists, the lowest energy conformation of known CCR5 antagonists e.g. SCH-C, 
SCH-D, and TAK-779 (Figure 17) were superimposed. When this background work was 
done, Maraviroc, Aplaviroc, and other CCR5 antagonists had not been reported then. 











                       
                       SCH-C                                                                         SCH-D (Vicriviroc) 
                          
                                                        TAK-779 
Figure 17: CCR5 antagonists 
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By superimposing their lowest energy conformations, a molecular scaffold (Figure 
18) was built. According to the molecular scaffold that was constructed, a secondary or 
tertiary amine moiety was present at a distance of 5-7 Å from an amide group. The 
secondary or tertiary amine was linked to a hydrophobic moiety (with or without a polar 
group attached) at a distance of 4.5-6 Å. An aromatic moiety was attached to the amide 
group at a distance of 3.5-5.5 Å. This entire molecular scaffold was in a bent form. 
 














polar moiety  
                                                 Figure 18: Molecular scaffold. 
To determine the interactions of this scaffold with the key amino acid residues of 
the receptor, the CCR5 antagonist SCH-D was docked into the receptor (Figure 19) with 
emphasis on evaluating the binding pocket interactions. The central amino group of the 
molecule formed a putative salt bridge with Glu283 on TM7. A lipophilic pocket which 
was formed by Ile 110, Leu107 which were a part of TM3, Tyr251 (TM6), and His289 
(TM7) served as the binding site for the hydrophobic moiety in the scaffold. The aromatic 
moiety in the molecular scaffold was located in an aromatic binding cavity formed by 
Phe112 (TM3), and Tyr244 and Trp248 which were a part of TM6.    
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Through the study of the binding interface of CCR5 receptor and SCH-D, it was 
observed that the interface between extracellular loop 2 (EL2) and spacer of the ligand 
which includes the hydrophobic moiety (Phe182) and a hydrophilic area (Ser179, Ser180) 
was not fully satisfied by SCH-D, nor by other known CCR5 ligands reported by that 
point of time.  Since extracellular loop 2 is very important for the binding of gp120 of 
HIV-1, novel ligands with a potential to interact with extracellular loop 2 were designed. 
The molecular scaffold was further elaborated to afford a novel skeleton (Figure 
20) based on the interaction of the important structural features of SCH-D with the amino 
acid residues in the binding pocket of the receptor. This new skeleton satisfied all the 
structural aspects necessary for interaction with the receptor.  
                                                                      
Figure 20: Novel skeleton 
The amino and amide moieties were connected by means of a trisubstituted phenyl 
ring. A hydrogen bond accepting group was introduced at R2 position. An aromatic moiety 
was introduced at R3. These structural features would satisfy the binding pocket 
requirements of extracellular loop 2. To verify the molecular design, a model compound 
(Figure 21) was formulated and docked into the binding cavity of the receptor (Figure 
22). 











                                          Figure 21: Model Compound 
 
 
        Figure 22: Model compound docked into binding pocket of CCR5. 
As shown in the above Figure 22, the model compound satisfies the requirements of the 
binding pocket of CCR5. Table 2 summarizes the possible substituents that could be 
    48 
 
introduced at R1, R2 and R3. The first round of chemical synthesis included the syntheses 
of 24 compounds. 
                                Table 2: Possible substituents at R1, R2, and R3 
Position           Substitution in the ligands 
R1 -)(CH2CH3)2, -)H2, -)COCH3, -)O2 
-CH3, -CH2CH3, -CH(CH3)2 
                   
R2 
R3 
                                          
These first 24 compounds were then tested for their anti-HIV activity. These 
compounds were tested in CEM-SS cells with laboratory derived strains (RF). In this 
assay, the virus, cells and drugs were incubated for six days. The cytopathic effect of HIV-
1 to cells with or without the compound was measured. A lead compound was obtained 
(Figure 23) which had an EC50 of 2.64 µM to inhibit HIV invasion. Based on this result, 
further molecular modeling studies were performed. 
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                                                       Figure 23: Lead compound. 
4.2 Molecular Modeling based drug design:  
Further molecular modeling studies were done based on the results obtained from 
the first round of chemical synthesis. More recently reported two CCR5 antagonists, 
Maraviroc and Aplaviroc, were docked into the homology model of CCR5 to study their 
binding mode.  
Maraviroc, developed by Pfizer, was docked into the homology model of CCR5 
receptor to study the binding interactions of its structural features with the binding pocket 
of the receptor. It was observed that Glu283, Tyr108, and Ile198 were important amino 
acid residues in the binding pocket of Maraviroc (Figure 24). This was supported by site-
directed mutagenesis study. Glu283 forms a putative salt bridge with the charged amino 
acid residue. E283A mutant showed 2000-fold loss of the binding ability of Maraviroc. 
Also, the binding of Maraviroc to CCR5 reduced markedly in I198A mutant. This may be 
due to a hydrophobic interaction between Maraviroc and Ile198. Tyr251, which is a part 
of the binding pocket, is believed to be flexible enough to move in and out depending on 
the size and electrostatic nature of the compound.77, 43 
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                                                    Maraviroc
 
 
        Figure 24: Binding mode of Maraviroc (purple) in the homology model of CCR5.77 
 
    51 
 
Aplaviroc, developed by Ono pharmaceuticals, was also docked into the CCR5 
receptor. It was observed that Aplaviroc had similar interactions with the binding pocket 
in the homology model of CCR5 (Figure 25). Ser180 may form hydrogen bond 
interaction with the molecule. The other key residues in the binding pocket of Aplaviroc 
were Tyr108, Phe112, Tyr251, and Glu283. Y108A drastically reduced the binding of 
Aplaviroc to the CCR5 mutant. An exclusive ionic or hydrogen bond interaction was 
observed between the carboxylic acid moiety and Lys197.77, 43, 78 
 Based on these docking studies of CCR5 antagonists into the homology model of 
the receptor, it was observed that there was a large hydrophobic binding pocket. This 
binding pocket was primarily constituted by Ile198 and Tyr 108. Mutation of these 
residues by alanine drastically reduced the binding affinity of Maraviroc and Aplaviroc. 
This hydrophobic binding pocket was able to accommodate bulky hydrophobic groups 
with or without polar substituents. 
 Further molecular modeling studies were carried wherein three CCR5 antagonists 
were aligned together in their lowest energy conformation. These included Maraviroc, 
Aplaviroc, and a compound designed and synthesized by our lab. This compound was 
similar to the lead compound (Figure 23) which only lacked the para nitro group. These 
three compounds are shown in Figure 26 and their alignment is shown in Figure 27.  
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                                                                      Aplaviroc 
 
      Figure 25: Binding mode of Aplaviroc (yellow) in the homology model of CCR5.77 
 
















                                   
Maraviroc                                                                      Aplaviroc 
 
Compound designed and synthesized by our lab which is similar to the lead compound 
(Figure 23). 
Figure 26: The three compounds that were aligned together. 
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Figure 27: Maraviroc (purple), Aplaviroc (orange) and compound from our lab (cyan) 
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On further analyzing, it was observed that the compound designed in our lab was 
in good alignment with the other two compounds. However; it lacked a longer arm at the 
end of the hydrophobic portion of the moiety. This additional hydrophobic arm probably 
fits into a hydrophobic binding pocket in the receptor. The need for this additional 
hydrophobic arm was consistent with molecular modeling and site-directed mutagenesis 
studies. Therefore, the molecular scaffold initially designed was further modified to 
accommodate additional bulky hydrophobic groups that would satisfy the hydrophobic 
binding pocket requirements of the receptor. 
4.3 Project Design:  
In order to satisfy the binding pocket requirements, bulky, and hydrophobic groups 
were introduced as R1 (Figure 28). 
                                                              
                       Figure 28: Molecular skeleton with new substituents as R1. 
To probe the electronic characteristics of the binding pocket, the molecular skeleton was 
modified such that various substituents could be incorporated as R1 (Table 3). Electron 
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would be substituted at R and phenyl and pyrazinyl groups would be substituted at R3. By 
doing so, twelve different final compounds would be obtained.  
                                      Table 3: Possible substituent at R1 and R3. 
R -H -CH3 -OCH3 -)O2 -CF3 -Cl 
R3 
                                                                
 
However, due to synthetic difficulties, only the - CF3 substituted compounds were 
synthesized. The synthesis of the remaining compounds was unsuccessful. The precursors 
that had to be prepared with the rest of the five different R1 substituents were either 
unstable or difficult to prepare. This observation was consistent with the commercial 
sources as it was noticed that none of them were available. Thus, some other 
commercially available similar precursors carrying bulky hydrophobic groups were 
incorporated. Figure 29 lists these commercially available precursors. 
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        Figure 29: The different commercially available hydrophobic substituents. 
4.4 Project Objectives: 
The primary objective of this project was to test our hypothesis that a bulky, 
hydrophobic group is necessary to satisfy the binding pocket requirements of the receptor. 
Fourteen CCR5 antagonists with varied substituents at R1 and R3 were synthesized to test 
this hypothesis. The synthetic route used for the synthesis of the previous batch of 
compounds was modified to introduce bulky, hydrophobic substituents at R1. Two 
aromatic groups, phenyl and pyrazinyl, were tested at R3.  
These CCR5 antagonists were then evaluated for their biological activity. Two 
assays, the calcium mobilization assay and anti-proliferation assay, were performed. The 
R R 
R = 
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calcium mobilization assay is a functional assay. The ability of CCR5 antagonists in 
inhibiting the intracellular calcium release stimulated by endogenous ligand, RANTES 
was evaluated. CCR5 antagonists that have a high affinity for the receptor will be capable 
of inhibiting the binding of RANTES to the receptor. The second assay was the anti-
proliferation assay which was tested in two different prostate cancer cell lines, PC-3, and 
M12. These prostate cancer cell lines express CCR5 on their cell surface. The goal of this 
assay was to test the anti-proliferative activity of the antagonists by binding to the CCR5 
receptor. The colorimetric reagent WST-1 was used in the anti-proliferation assays. 
The data obtained from these assays would help in testing our hypothesis as well 
as establishing a structure-activity relationship to facilitate the design of the next 
generation of compounds.  
59 
5. Results and Discussion 
5.1 Chemical Synthesis of CCR5 Antagonists: 
 The synthetic route used to prepare the previous batch of compounds was adopted 
to prepare the new series of CCR5 antagonists. Two series of compounds were prepared 
which differed in the substitution at R3 position. The first series consisted of phenyl 
substituted compounds and the second series consisted of pyrazinyl substituted 
compounds. The first two reactions of the synthetic route are outlined in Figure 30. 
 
 
                          Figure 30: Substitution and Grignard reactions. 
 
The first reaction in the synthetic route was a substitution reaction where the 
hydroxyl group of 4-bromophenol (1) reacted with isopropyl bromide to form an 
isopropoxyl moiety. This reaction was performed with dimethyl formamide (DMF) as the 
solvent. The reaction mixture was refluxed overnight at 90ºC. The work up involved 
washing the reaction mixture with brine (50 mL) followed by washing with water (25 
mL). Compound 2 was obtained in 86% yields. 
2 1 3 
K2CO3, DMF, reflux, 
100ᴼC 
Mg, I2, THF, NH4Cl, HCl, reflux 
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The Grignard reaction was then conducted for conversion of 1-bromo-4-
isopropoxybenzene (2) to 1-benzyl-4-(4-isopropoxyphenyl)-1,2,3,6-tetrahydropyridine 
(3). The experimental set-up of the Grignard reaction is shown in Figure 31. This was a 
challenging reaction as the reaction atmosphere had to be anhydrous and devoid of 
oxygen. This is because Mg, which was used in the reaction to form the Grignard reagent, 
decomposes in the presence of oxygen. All the glassware needed for this reaction was 
dried and placed in an oven overnight. Small pieces of Mg were cut just before the 
reaction was performed. Vacuum was introduced in the entire experimental set up to 
remove any trace moisture. This was followed by flushing the experimental setup with 
nitrogen gas.  
The alkyl bromide, (2) prepared from the previous reaction, was added drop-wise 
over a period of 30 minutes to a mixture of Mg pieces and iodine in tetrahydrofuran 
(THF), which was the solvent of this reaction. This led to the formation of the Grignard 
reagent. This was followed by addition of the ketone, 1-benzyl-4-piperidone, to form the 
product (3). The resulting mixture was refluxed for about 3 hours with ammonium 
chloride and 6N hydrochloric acid. This was done to consume any remaining unreacted 
Grignard reagent. This reaction had a yield of 65%. The yield did not improve even if the 
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                           Figure 31: Experimental set-up for Grignard reaction.76 
 





Condenser for refluxing 
Round bottom flask with Mg, I2 and 
THF 
N2 out 
N2 in Alkyl bromide 
added through 
funnel 
3 4 5 
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Debenzylation and double bond reduction was the next step in the synthetic route 
(Figure 32). This reaction was carried out using a Parr-hydrogenator in an atmosphere of 
hydrogen. The catalyst used was Pd/C (10%). This reaction was tried out many times but 
the reaction did not proceed to completion. Literature reported such a reaction to be 
extremely slow which would take some days or weeks to go to completion. Despite 
running the reaction for 5-7 days, thin layer chromatography (TLC) showed that the 
starting material (3) was not consumed, thus, indicating that the reaction had not taken 
place.  
Therefore, the starting material used in the reaction was analyzed. Earlier, the 
starting material had been purified by column chromatography. To further purify the 
starting material, it was re-crystallized from hot ethanol. Despite carrying out the reaction 
with the re-crystallized starting material, the reaction did not proceed to completion. The 
starting material (3), a tertiary amine, was then converted to the corresponding 
hydrochloride salt by adding 1.3 equivalents of 1M HCl. The resulting salt was then used 
in the reaction instead of the free base. The reaction was allowed to run for seven days at 
an elevated temperature of about 500C by using a heating pad. 10% of the catalyst was 
used. At the end of seven days, TLC showed that the starting material was totally 
consumed. The consumption of the starting material was accompanied by the appearance 
of a new spot on TLC. Separation was done by column chromatography using a 20:1 
dichloromethane methanol solvent system with 10% ammonium hydroxide. 
Characterization by NMR confirmed the new spot to be the product, compound 4. This 
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reaction had a yield of 84%. Therefore, the key factors for this reaction to proceed to 
completion were purification of the starting material and using the tertiary amine starting 
material as the hydrochloride salt. 
Debenzylation of the tertiary amine (3) leads to a secondary amine (4) which was 
not very stable. Thus, protection of the secondary amine was the next step in the overall 
synthetic route (Figure 33). Trifloro acetic anhydride was used as the protecting agent. 
The reaction was carried out in an ice-water bath with dichloromethane as the solvent. 
Molecular sieves were added to the reaction mixture to remove any residual of water. The 
reaction proceeded from 0oC to room temperature. It was allowed to react for about 12 
hours. The product of this reaction (5) was obtained in yields of 90%. 
 
 
Figure 34: Nitration and reduction reactions  
Introduction of a single nitro group on the benzene ring ortho to the isopropxyl 
moiety was the next reaction in the synthetic route (Figure 34). The reaction was carried 
out at a temperature of about -350C in the presence of nitric acid. This temperature was 
maintained in an acetone-dry ice bath. Initially the temperature was allowed to go as low 
7 6 5 
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as -700C. At this temperature, nitric acid was added. The temperature was then raised to -
350C by removing pieces of dry ice from the acetone-dry ice bath. The temperature was 
maintained constant for six hours for the reaction to proceed to completion. The reaction 
was quenched by pouring the contents into ice. The organic phase was extracted with 
dichloromethane. Product 6 was obtained in 80% yields.  
  The nitro group in compound 6 had to be reduced to form the corresponding 
primary amine in the next reaction (Figure 34). This was done in an atmosphere of 
hydrogen using the Parr hydrogenator with methanol as the solvent. Pd/C (10%) was used 
as the catalyst. The reaction was carried out for about 5 hours. The work up included 
filtering the reaction mixture through celite to afford removal of the catalyst. The product 
7 was obtained in a yield of 50%.  
The primary amine in 7 was then coupled with an acid to form the amide bond. 
The acid used was either benzoic acid or pyrazine-2-carboxylic acid (Figure 35). There 
were two factors which were important to this reaction. The first factor was absence of 
water and hence molecular sieves were used. The second factor was the sequence in which 
the reactants had to be added. The acid (either benzoic acid or pyrazine-2-carboxylic acid) 
was stirred with EDCI (-(3-dimethylaminopropyl)-’-ethylcarbodiimide hydrochloride), 
HOBT (1-hydroxybenzotriazole hydrate), TEA (triethylamine), DMF and molecular 
sieves in an ice-water bath for about 15 minutes initially. This was followed by the 
addition of the primary amine (6) to the activated carboxylic acid. The reaction was 
allowed to proceed to room temperature overnight. Compounds 8 or 9 were obtained when 
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benzoic acid or pyrazine-2-carboxylic acid was used respectively. The benzoic acid 
coupled product (8) was obtained in 87.3% yield whereas the pyrazine-2-carboxylic acid 
coupled product (9) was obtained in yields of 84.6%. 
 
 
                   
                 Figure 35: Amide formation and base catalyzed de-protection reactions. 
 
7 8 9 
11 10 
12-25 
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 De-protection of the piperidine amine to form a secondary amine was the next 
step. This was done using methanol and water mixture as the solvent system. Potassium 
carbonate was used as the base. The reaction mixture was refluxed at about 1000C for 3 
hours. The reaction mixture was then evaporated to remove methanol and water. This was 
followed by dissolving the contents in dichloromethane followed by extraction with a 
saturated solution of sodium bicarbonate. On evaporating the organic phase, the product 
precipitated. The product, compounds 10 or 11, was obtained in yield of around 98.8%.  
The last step in the synthetic route was coupling of diaryl ether moieties which had 
different substituents at R1 to the secondary amines 10 and 11 (Figure 36).  
                         
Figure 36: Diaryl ethers with six different substituents at R1. 
These diaryl ether side chains had to be prepared in two steps. The first step was an 
Ullmann coupling reaction. This involved the coupling between p-cresol and 
bromobenzenes with different substituents at R1. Figure 37 shows the different 
bromobenzenes that were to be coupled to p-cresol. 
R
1 
= -H, -CH3, -OCH3, -)O2, -CF3, -Cl 
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Figure 37: Bromobenzenes to be coupled with p-cresol. 
The Ullmann coupling reaction was used to couple the bromobenzenes with an 
electron donating group at R1 to p-cresol.  In this reaction, cesium carbonate was the base, 
copper bromide was used as the catalyst and N-methylpyrrolidone (NMP) was the solvent. 
The reaction mixture was refluxed for 16 hours at 1600C under nitrogen protection. The 
resulting diaryl ether product was purified by column chromatography. Bromobenzenes 
with –H, -OCH3, and –CH3 were coupled to p-cresol by the Ullmann coupling reaction 
(Figure 38).81 
 
Figure 38: Ullman coupling reaction for electron donating groups.81 
The Ullmann coupling reaction for electron withdrawing groups was done in a 
microwave at 1250C for 25 minutes (Figure 39). The microwave reaction was reported in 
literature due to the reduced reactivity of those bromobenzenes with an electron 
withdrawing group at R1. The base used in the reaction was potassium tert-butoxide, the 
160ºC, 16 hours, N2 
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catalyst was copper iodide and tetramethyl ethylenediamine (TMEDA) was the ligand 
used.  However, only the –CF3 substituted bromobenzene coupled to p-cresol. The 
remaining substituted bromobenzenes did not react under microwave conditions 
successfully.  Thus, refluxing the reaction mixture overnight at 125ᴼC was tried. Under 
these conditions, the starting material was consumed and the reaction proceeded to 
completion.82  
                 
Figure 39: Ullmann Coupling reaction for electron withdrawing groups.82 
The methyl group in the diaryl ether had to be brominated to afford a benzyl 
bromide which could be coupled to the secondary amine. In the presence of NBS (N-
bromosuccinimide) and azobisisobutyronitrile (AIBN) with CCl4 as the solvent, the 
methyl group would be brominated to form –CH2Br.
83 However, only the reaction with the 
–CF3 substituted starting material proceeded to completion. The remaining diaryl ethers 
that were prepared either did not proceed to completion or were unstable and hence could 
not be purified. The reason for this may be the fact that the free radical intermediate 
formed in this reaction is either destabilized or consumed prior to reaction with NBS. 
Thus, bromination of these side chains was discontinued and other commercially available 
benzyl bromides or benzyl chlorides were applied to prepare the final compounds. Six 
DMF, 125ºC 
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different commercially available benzyl bromides or benzyl chlorides (b through g) were 
coupled to compounds 10 and 11. 
 
 
                          
Figure 40: Different substituents that were attached to 10 and 11 
a b c d 
e f g 
R = 
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Fourteen final compounds were prepared (Figure 41). Two methods were used for 
the preparation of the final compounds. The first method utilized potassium carbonate as 
the base for abstraction of the proton from the secondary amine, compounds 10 and 11 
(Figure 42). DMF was used as the solvent. The reaction was allowed to run overnight. It 
proceeded from 00C to room temperature. Those reactions which had a substituent at the 
para position at R proceeded to completion. 
 
Figure 42: Reaction for para substituents at R. 
However, the synthesis of compounds 14, 15, 20, 21, 22 and 23 failed when this 
method was used. TLC showed that the starting material had not reacted at all even after 
two days. Steric hindrance was thought to be the reason due to which compounds 20 and 
21 could not be prepared using this method. The bulky phenyl group ortho to –CH2Br- 
would hinder the secondary amine (compound 10 and 11) from reacting with it. Literature 
search did not provide any help as no such reaction was reported. It was postulated that 
refluxing the reaction mixture may overcome the steric hindrance. Methanol, with a 
boiling point of just 650C as compared to DMF with a boiling point of 1530C, was chosen 
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as the solvent. Also, methanol is not as sticky as DMF. The latter is quite difficult to 
remove form the reaction mixture. Since potassium carbonate, an inorganic base, is not 
very soluble in methanol an organic base, such as pyridine, which is soluble in methanol, 
was chosen. On carrying out this reaction at a temperature of 700C overnight resulted in 
completion of the reaction. The excess of pyridine left unreacted in the reaction mixture 
was removed by washing with 1N HCl. On purifying by column chromatography, 
compounds 20 and 21 were obtained (Figure 43).  
              Compounds 14, 15 and 22, 23 could not be prepared using the first method with 
potassium carbonate as the base and DMF as the solvent. Both of these compounds have 
an electron donating group at the meta position. This would deactivate the entire moiety 
and render it un-reactive towards the reaction. Once again, no such reaction was reported 
in literature. The method used to prepare compounds 20 and 21 was tried for the 
preparation of 14, 15, 22 and 23 as well. On refluxing over night with pyridine as the base 
in methanol, the compounds 14, 15 and 22, 23 were obtained (Figure 43).  
 
Figure 43: Reaction for ortho and meta substituted R. 
Methanol, 
reflux 
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            Compounds 12 and 13 were prepared in two additional steps. The first step was an 
Ullmann coupling reaction (Figure 44). This gave compound 26, which is diaryl ether. 
The methyl group of 26 had to be brominated in the next step. The resulting benzyl 
bromide (compound 27) was used for coupling to the secondary amine to obtain 
compounds11 and 12 (Figure 44). 
 
             
                             Figure 44: Ullmann coupling and bromination reactions. 
All the final compounds (compounds 12 through 25) were obtained in their free 
base form. They were then converted to the corresponding hydrochloride salts by using 
1.3 equivalents of 1M HCl in ether solution. The final compounds were characterized by 
proton and carbon nuclear magnetic resonance spectroscopy (NMR), infrared (IR) 
spectroscopy, mass spectroscopy, and high performance liquid chromatography (HPLC). 
Also, their melting points were recorded. The hydrochloride salts of all the fourteen final 
compounds were used to perform biological screenings.  
5.2 Biological Screening: 
26 
27 
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The fourteen CCR5 antagonists that were synthesized were evaluated for their 
biological activity. Two assays were performed: the calcium mobilization assay and the 
anti-proliferation assay.  
5.2.1 Calcium Mobilization Assay: 
The calcium mobilization assay, a functional assay, was conducted to evaluate the 
ability of the compounds to inhibit the RANTES induced intracellular calcium release. 
The cell line used was MOLT-4 which expresses the chemokine receptor CCR5 on its 
membrane. The dye used in this assay was Fluo-4, a fluorescent dye, which has high 
affinity for calcium ions. This dye has a very low emission at rest; however there is a large 
increase in the emission intensity when it binds calcium. On stimulation of the cells with 
the agonist RANTES, it increases the intracellular levels of calcium. The changes in 
calcium concentrations can be detected by the Fluo-4 dye.81 CCR5 antagonists bind to the 
receptor thus, preventing RANTES from interacting with the receptor. As a result, the 
increase in intracellular calcium levels is inhibited leading to lower emission intensity of 
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The IC50 values obtained for the antagonists are summarized in the following Table 4. 
                         Table 4: IC50 values from the calcium mobilization assay 
Compound IC50 (µM) 
12 57.17± 12.81 
13 189.87± 139.15 
14 46.49± 28.75 
15 28.60± 14.33 
16 51.74± 17.04 
17 54.87± 18.93 
18 61.44± 53.16 
19 15.41± 6.45 
20 169.47± 112.15 
21 36.91± 8.85 
22 >200 
23 190.81± 152.80 
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24 26.75± 12.40 
25 59.00± 41.40 
Maraviroc 4.13± 0.02 
  
Discussion:  
Based on the IC50 values from the calcium mobilization assay, compound 19 was 
the most potent CCR5 antagonist in inhibiting the intracellular calcium release stimulated 
by RANTES with an IC50 of 15.41 µM. This can be interpreted that compound 19 was 
able to inhibit the binding of 50% RANTES to the CCR5 receptor at a concentration of 
15.41 µM. 
         
                         Initial lead                                                             19 
Figure 45: Our initial lead and compound 19. 
The IC50 of the initial lead in the calcium mobilization assay was 65.7 µM. Thus, 
compound 19 has a greater ability to bind to CCR5 and inhibit the calcium release 
stimulated by RANTES. On comparing the structure of the two antagonists, we can infer 
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that introduction of a hydrophobic group at R1 has increaed the compound’s affinity for 
the CCR5 receptor. Besides compound 19, most of the other compounds 12, 14, 15, 16, 
17, 18, 21, 24 and 25 have an IC50 value lower than the initial lead. This further 
strengthens our hypothesis that a large, hydrophobic binding pocket is present in the 
CCR5 receptor which is capable of accomodating bulky substituents. However, a clear 
structure-activity relationship can not be established. This is due to the small number of 
ligands (fourteen) that were synthesized and tested.  
5.2.2 Anti-proliferation Assay: 
The anti-proliferation assay was performed to determine the anti-prostate cancer 
activity of the CCR5 antagonists synthesized. Two different prostate cancer cell lines 
which express the CCR5 receptor were used. These were PC-3 and M12. The two cell 
lines had a similar assay protocol that had to be followed.  
WST-1 reagent has a tetrazolium salt in its structure which is cleaved by 
mitochondrial dehydrogenase which leads to the formation of formazan dye (Figure 46). 
The formazan dye is soluble in water and has a characteristic dark red color to it. Only 
those cells which are viable contain the mitochondrial dehydrogenase. Hence, only those 
wells with viable cells can facilitate the formation of the dark red colored formazan dye.80 
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 The fourteen compounds that were tested are shown in Figure 41, and the IC50 
values obtained for each compound in each cell line is represented in the Table 5. The 
concentration range that was tested for both PC-3 and M12 were 3 µM, 10 µM, 30 µM 
and 100 µM.                          







Figure 46: Role of WST-1 in the Anti-proliferation Assay.80  
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Table 5: The IC50 values for PC-3 and M12 cell lines.  
Compound PC-3 IC50 (µM)  M12IC50 (µM) 
12 66.10 ± 9.03  37.52± 2.73 
13 68.80 ± 7.13  62.57± 2.62 
14 97.50 ± 1.14  20.04± 0.42 
15 >100  49.13± 2.58 
16 78.90 ± 25.30  >200 
17 88.10 ± 15.90  >200 
18 77.80 ± 18.70  >200 
19 35.80 ± 7.14  56.33± 11.01 
20 89.00 ± 15.0  152.97± 10.07 
21 >100  68.63± 1.84 
22 >100  72.86± 1.82 
23 >100  85.12± 1.66 
24 >100  25.58± 0.29 
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25 >100  >200 
Anibamine 1.13± 0.01  3.26 ±0.35 
                              
Discussion: 
Based on the IC50 values obtained from the calcium mobilization assay, compound 
19 was the most potent CCR5 antagonist in inhibiting the intracellular calcium release 
stimulated by RANTES with an IC50 of 15.41 µM. This was consistent with the IC50 value 
obtained from the anti-proliferation assay in the PC-3 cell line where compound 19showed 
an IC50 of 35.80 µM, as the most active one among others on its anti-proliferative activity 
in PC-3 cell line. To be noticed, our initial lead compound had an IC50 of greater than 100 
µM in the anti-proliferation assay in the PC-3 cell line. Thus, our hypothesis regarding the 
presence of a hydrophobic binding pocket in the receptor is partially supported by the data 
obtained. Besides compound 19, other ligands 12, 13, 14, 16, 17, 18, and 20 also showed 
higher anti proliferation activity than our initial lead compound in the PC-3 cell line.  
In the M12 cell line, the anti-proliferative activity of compound 19 was much 
lower with an IC50 of 56.33 µM. However, the proliferation of M12 cells were greatly 
inhibited by compounds 14and 24 with IC50 values of 20.04 µM and 25.58 µM 
respectively (Figure 47). Our initial lead compound had an IC50 of 32.66 µM in the anti-
proliferation assay in M12 cell lines. Thus, two compounds (14, 24) were more potent 
than the lead as of prostate cancer cell proliferation agents.  
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A structure-activity relationship that could be established from the calcium 
mobilization assay as well as the anti-proliferation assay was the observation that in 
general pyrazinyl substituted ligands showed better activity than the phenyl substituted 
compounds. For example, compounds 18 and 19 (Figure 41) shared the same bulky 
hydrophobic para biphenyl moiety present in their structure. The only difference in their 
structures was the present of a phenyl or a pyrazinyl group at R3 position. However, 
compound 19 has an IC50 value of 15.41 µM and compound 18 has an IC50 value of 61.44 
µM in the calcium mobilization assay (Table 4). This observation is also consistent with 
our initial lead compound which has a pyrazinyl group present in its structure.  
                                         
 
                                           Figure 47: Compounds 19, 14, and 24. 
19 14 
24 
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It can be clearly seen that the activity of the same compound showed different 
trend regarding different cell lines. Compound 19 was the most potent CCR5 antagonist in 
the calcium mobilization assay and had the best anti-proliferative activity in the PC-3 
prostate cancer cell line among others. However, when tested in the M12 prostate cancer 
cell line, antagonist 19 showed lower anti-proliferative activity compared with other 
ligands. Similarly, compounds 4 and 14 were not the most potent antagonists in the 
calcium mobilization assay while they showed the highest anti-proliferative activity in the 
M12 prostate cancer cell line. 
This difference in activity of the same compound in different cell lines can be 
affected by various factors. One reason for the difference in activity could be the varied 
expression of CCR5 in each cell line. This difference amongst cell lines in the expression 
level of CCR5 could affect the function of our compounds. For example, PC-3 cell 
expresses lower level of CCR5 than M12 one28 while most of the compounds showed 
better anti-proliferative activity in M12 cells than in PC-3 cells. Also, the downstream 
signaling pathways may compensate differently to the antagonism of CCR5 among 
different cancer cell lines. 
Second, CCR5 antagonism may not necessarily correlate with inhibition of 
proliferation of prostate cancer cell lines. Some potent CCR5 antagonists, e.g. Maraviroc, 
did not show significant anti-prostate cancer proliferation activity under our experimental 
conditions. The G-protein-coupled receptors are capable of adopting multiple active states. 
They can be stabilized differently by the ligands which are specific so that only a subset of 
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the entire signaling pathway can be selectively activated. This concept is known as 
“functional selectivity”.85 Each individual ligand leads to differential and independent 
coupling of the GPCR to different intracellular effectors.86 In the case of the ligands 
synthesized in our lab, an explanation for the differential inhibition in calcium 
mobilization activity and anti-proliferative activity could be functional selectivity of 
ligands. Despite binding to the same receptor, they cause distinct functional changes. One 
of the mechanisms could be atypical conformational changes induced by ligand binding.87 
This may result in conformational change that may differentially affect the anti-
proliferation activity and calcium mobilization activity. 
A comprehensive structure-activity relationship could not be established due to a 
limited number of ligands synthesized in this series. This limits the number of factors that 
can be accounted for to establish the quantitative structure activity relationship though 
some qualitative conclusion can be drawn. However, these studies are the beginning of a 
thorough analysis of the CCR5 antagonist binding pocket in the CCR5 receptor. Further 
examination may result in identification of a new lead compound to develop our next 




6. Experimental Section 
6.1 Chemical Synthesis: 
Melting points were determined on a Fisher-Scientific melting point apparatus. 
1H-NMR and 13CNMR spectra were obtained on a Brucker 400 MHz spectrometer and 
tetramethylsilane was used as an internal standard. Infrared spectra were obtained on a 
Smart iTR diamond ATR spectrometer. Column chromatography was performed on silica 
gel (grade 60 mesh; Bodman Industries, Aston, PA). Routine thin-layer chromatography 
(TLC) was performed on silica gel GHIF plates (250 µm, 2.5 x 10 cm; Analtech Inc., 
Newark, DE). Preparative HPLC was performed on a Varian Microsorb 100-5 C18 
column (250 x 4.6mm), using Prostar 325 UV-Vis (254 nm) as the detector.  
 
6.1.1 Synthesis of Intermediates: 
1-bromo-4-isopropoxybenzene (5).  
 
To a solution of 1 equivalent of 4-bromophenol (10.0 g, 57.803 mmol) in 15 mL 
dimethylformamide (DMF), 1.2 equivalents of potassium carbonate (9.58 g, 69.38 mmol) 
and 1.5 equivalents of 2-bromopropane (10.66 g, 8.1312 mL, d. 1.311 g/mL, 86.66 mmol) 
were added while stirring. The suspension was refluxed for 24 hours at 1000C on a pre-
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heated mantel. The resulting suspension was filtered; the filtrate was concentrated under 
vacuum to remove DMF. The residue was partitioned between water (40 mL) and 
dichloromethane (80 mL). The organic layer was washed with brine, dried over sodium 
sulfate and concentrated to give 1-bromo-4-isopropoxybenzene (9.29 g, 86% yield) as 
colorless oil. 1H NMR (400 MHz, CDCl3) δ 7.36 (m, 2H), 6.77 (m, 2H), 4.49 (m, J= 6.05 
Hz, 1H), 1.33 (d, J= 6.08, 6H). 
1-benzyl-4-(4-isopropoxyphenyl)-1,2,3,6-tetrahydropyridine (7). 
A solution of 1.1 equivalents of 1-bromo-4-isopropoxybenzene (7.5 g, 40.1 mmol) 
in 5 mL tetrahydrofuran (THF) was added dropwise over a period of 30 minutes to a 
stirred mixture  
                                                                       
 of magnesium (0.88 g, 36.4 mmol) and iodine (catalytic amount) in a 500 mL flask. The 
resulting suspension was refluxed at 900 C for 30 minutes on a pre-heated mantel. A 
solution of 0.9 equivalents of 1-benzyl-4-piperidone (6.2 g, 32.8 mmol) was then added to 
the suspension drop wise over a period of 30 minutes. The suspension was refluxed at 900 
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C for 40 minutes. After cooling down, ammonium chloride (60 mL) and water (30 mL) 
were added. The mixture was allowed to stand for some time followed by the addition of 
60 mL of 6N HCl. This suspension was refluxed at 1000 C for 3 hours. The suspension 
was concentrated in vacuum to remove THF. The product precipitated from the water 
layer. On filtration, the crude product was obtained. This was purified by column 
chromatography on silica gel with a hexane: ethyl acetate (20: 1) solvent system to obtain 
pure 1-benzyl-4-(4-isopropoxyphenyl)-1,2,3,6-tetrahydopyridine (6.6 g, 65.4% yield) as a 
pale yellow solid. 1H NMR (400 MHz, CDCl3) δ 7.72 (m, 2H), 7.46 (m, 3H), 7.29 (m, 
2H), 6.85 (m, 2H), 5.87 (s, 1H), 4.55 (m, J= 6.08 Hz, 1H), 4.23 (m, 2H), 3.97 (m, 1H), 
3.62 (m, 1H), 3.50 (m, 1H), 3.15 (m, 2H), 2.68 (m, 1H), 1.33 (d, J=6.04 Hz, 6H).  
4-(4-isopropoxyphenyl)piperidine (11). 
 
A solution of 1 equivalent of 1-benzyl-4-(4-isopropoxyphenyl)-1,2,3,6-
tetrahydropyridine (6 g, 19.51 mmol) in methanol was hydrogenated in a 500 mL 
hydrogenation flask at 500C-600C in the presence of 10% w/w Pd/C (10%), HCl (0.372 
mmol/mL) and HBr (0.2546 mmol/mL) under hydrogen atmosphere at 57 psi for 5 days. 
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The resulting suspension was filtered over celite to remove catalyst. The filtrate was 
neutralized with sodium carbonate and concentrated to give 4-(4-
isopropoxyphenyl)piperidine (4.19 g, 84% yield) as a pale yellow solid. 1H NMR 
(400MHz, CDCl3): δ 7.11 (m, 2H), 6.8 (m, 2H), 4.4 (m, J= 6.08 Hz, 1H), 3.18 (m, 2H), 






O CF3  
 A solution of 1 equivalent of 4-(4-isopropoxyphenyl)piperidine (4 g, 15.63 mmol) and 
2.2 equivalents of pyridine (2.71 g, 34.399 mmol) in dichloromethane in a 200 mL flask 
were stirred on an ice-bath for ten minutes with molecular sieves. To this solution, 1.1 
equivalents of trifluoroacetic anhydride (3.61 g, 17.19 mmol) were added dropwise over a 
period of ten minutes. After stirring at room temperature overnight, the solution was 
filtered, the filtrate was washed with 1N HCl twice, brine and dried over sodium sulfate. 
The resulting dichloromethane solution was concentrated to give 2,2,2-trifluoro-1-(4-(4-
isopropoxyphenyl)piperidine-1-yl)ethanone (4.43 g, 90% yield) as a reddish-brown oil. 1H 
NMR (400MHz, CDCl3): δ 7.08 (m,  2H), 6.83 (m, 2H), 4.66 (m, 1H), 4.5 (m, J= 6.08 Hz, 
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1H), 4.11 (m, 1H), 3.22 (m, 1H), 2.79 (m, 2H), 1.95 (m, 2H), 1.67 (m, 2H), 1.32 (d,  J= 
6.08 Hz, 6H). 
2,2,2-trifluoro-1-(4-(4-isopropoxy-3-nitrophenyl)piperidine-1-yl)-ethanone (16).  
 
A solution of 1 equivalent of 2,2,2-trifluoro-1-(4-(4-isopropoxyphenyl)piperidine-1-
yl)ethanone (4 g, 12.68 mmol) in 20 mL acetic anhydride in a 100 mL flask was stirred in 
a dry-ice acetone bath at -700C for fifteen minutes. To this solution, 10 equivalents of 
concentrated nitric acid (7.99 g, 5.28 mL, d. 1.512 g/mL, and 126.8 mmol) were added 
drop wise over a period of thirty minutes. The reaction mixture was stirred at -300 C for 6 
hours. The mixture was then poured into ice (50 mL). The water phase was extracted with 
100 mL dichloromethane three times, washed with brine and dried over sodium sulfate. 
On concentration, 2,2,2-trifluoro-1-(4-(4-isopropoxy-3-nitrophenyl)piperidine-1-yl)-
ethanone (3.65 g, 80% yield) was obtained as a pale yellow oil. 1H NMR (400MHz, 
CDCl3): δ 7.60 (d, J=2.32, 1H), 7.31 (dd, J= 2.36, J= 8.68 Hz, 1H), 7.03 (d, J= 8.72 Hz, 
1H), 4.70 (m, 1H), 4.64 (m, J=6.04 Hz, 1H), 4.14 (m, 1H), 3.23 (m, 1H), 2.82 (m, 2H), 
1.95 (m, 2H), 1.67 (m, 2H), 1.37 (d, J=6.04, 6H). 
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1-(4-(3-amino-4-isopropoxyphenyl)piperidin-1-yl)-2,2,2-trifluoroethanone (33).  
 
A solution of 1 equivalent of 2,2,2-trifluoro-1-(4-(4-isopropoxy-3-
nitrophenyl)piperidine-1-yl)-ethanone (3.5 g, 9.71 mmol) and 1.2 equivalents of HCl 
(0.425 g, 0.4051 mL, d. 1.049 g/mL, 11.65 mmol) in methanol was hydrogenated in a 500 
mL hydrogenation flask at room temperature. The reaction was carried out in the presence 
of 10% Pd/C (10%) under an atmosphere of hydrogen for 10 hours. The resulting 
suspension was filtered over celite to remove catalyst. The filtrate was neutralized with 
sodium carbonate and concentrated to give 1-(4-(3-amino-4-isopropoxyphenyl)piperidin-
1-yl)-2,2,2-trifluoroethanone (1.76 g, 55% yield) as a pale yellow oil. . 1H NMR 
(400MHz, CDCl3): δ 7.53 (d, J= 1.96 Hz, 1H), 7.12 (dd, J= 1.96 Hz, J= 8.6 Hz, 1H), 6.92 
(d, J= 8.64 Hz, 1H), 4.65 (m, 1H), 4.48 (m, J= 6.04 Hz, 1H), 4.11 (m, 1H), 3.19 (m, 1H), 
2.79 (m, 2H), 1.95 (m, 2H), 1.65 (m, 2H), 1.39 (d, J= 6.04 Hz, 6H).  
)-(2-isopropoxy-5-(1-(2,2,2,-trifluoroacetyl)piperidine-4-yl)phenyl)benzamide(34):  











On an ice-water bath, to a solution of 2 equivalents of benzoic acid (638.62  mg, 
5.598 mmol) in DMF (2 mL), 1.5 equivalents of N-(3-dimethylaminopropyl)-N’-
ethylcarbodiimide hydrochloride (EDCI) (804.79 mg, 4.198 mmol), 1.5 equivalents of 1-
hydroxybenzotriazole hydrate (HOBT) (567.27 mg, 4.198 mmol), 3 equivalents of 
triethylamine (TEA) (849.69 mg, 1.16 mL, d. 0.726 g/mL, 8.397 mmol) and molecular 
sieves (4Å) were added. This mixture was stirred under N2 protection for 15 minutes. A 
solution of 1 equivalent of 1-(4-(3-amino-4-isopropoxyphenyl)piperidin-1-yl)-2,2,2-
trifluoroethanone (927 mg, 2.799 mmol) in DMF (2 mL) was added to the above reaction 
mixture. This was allowed to react overnight and proceed from 00C to room temperature. 
The resulting mixture was filtered through celite and DMF was evaporated. This was 
dissolved in dichloromethane, washed with brine, dried over sodium sulfate and 
concentrated. The residue was purified by column chromatography on silica gel with a 
hexane: ethyl acetate (5:1) solvent system to obtain pure N-(2-isopropoxy-5-(1-(2,2,2,-
trifluoroacetyl)piperidine-4-yl)phenyl)benzamide (1.1 g, 87.3% yield) as a pale yellow 
powder. 1H NMR (400MHz, CDCl3): δ 8.67 (br, 1H), 8.49 (s, 1H), 7.87 (m, 2H), 7.52 (m, 
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3H), 6.87 (s, 2H), 4.69 (m, 1H), 4.63 (m, J= 6.08 Hz, 1H), 4.13 (m, 1H), 3.22 (m, 1H), 
2.82 (m, 2H), 2.01 (m, 2H), 1.73 (m, 2H), 1.40 (d, J= 6.04 Hz, 6H).  
)-(2-isopropoxy-5-(1-(2,2,2,-trifluoroacetyl)piperidine-4-yl)phenyl)pyrazine-2-
carboxamide (61):  
 
On an ice-water bath, to a solution of 2 equivalents of pyrazine-2-carboxylic acid 
(755.53 mg, 6.039 mmol) in DMF (2 mL), 1.5 equivalents of N-(3-dimethylaminopropyl)-
N’-ethylcarbodiimide hydrochloride (EDCI) (868.06 mg, 4.528 mmol), 1.5 equivalents of 
1-hydroxybenzotriazole hydrate (HOBT) (611.86 mg, 4.528 mmol), 3 equivalents of 
triethylamine (TEA) (916.47 mg, 1.26 mL, d. 0.726 g/mL, 9.057 mmol) and molecular 
sieves (4Å) were added. This mixture was stirred under N2 protection for 15 minutes. A 
solution of 1 equivalent of 1-(4-(3-amino-4-isopropoxyphenyl)piperidin-1-yl)-2,2,2-
trifluoroethanone (1 g, 3.019 mmol) in DMF (2 mL) was added to the above reaction 
mixture. This was allowed to react overnight and proceed from 00C to room temperature. 
The resulting mixture was filtered through celite and DMF was evaporated. This was 
dissolved in dichloromethane, washed with brine, dried over sodium sulfate and 
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concentrated. The residue was purified by column chromatography on silica gel with a 
hexane: ethyl acetate (5:1) solvent system to obtain pure N-(2-isopropoxy-5-(1-(2,2,2,-
trifluoroacetyl)piperidine-4-yl)phenyl)pyrazine-2-carboxamide (1.1 g, 84.6% yield) as a 
pale yellow powder. 1H NMR (400MHz, CDCl3): δ 10.40 (br, 1H), 9.49 (d, J= 1.4Hz, 
1H), 8.79 (d, J= 2.4 Hz, 1H), 8.62 (d,d J=1.52 Hz, J=2.4 Hz, 1H), 8.51 (s, 1H), 6.90 (s, 
2H), 4.68 (m, 1H), 4.62 (m, J= 6.04 Hz, 1H), 4.13 (d, 1H), 3.24 (t, 1H), 2.85 (m, 2H), 2.01 
(m, 2H), 1.73 (m, 2H), 1.42 (d, J= 6.08 Hz, 6H). 










To a solution of 1 equivalent (200 mg, 0.5822 mmol) N-(2-isopropoxy-5-(1-
(2,2,2,-trifluoroacetyl)piperidine-4-yl)phenyl)benzamide in methanol (20 mL) and water 
(5 mL), 5.2 equivalents of potassium carbonate (417.81 mg, 3.027 mmol) was added. The 
reaction mixture was refluxed at 1000C for 2 hours. Methanol and water were evaporated 
off followed by dissolving the contents in dichloromethane. This solution was then 
washed with saturated sodium bicarbonate solution, brine, dried over sodium sulfate and 
concentrated to obtain pure N-(2-isopropoxy-5-(piperidinn-4-yl)phenyl)benzamide (152 
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mg, 98.9% yield) as a pale yellow solid. 1H NMR (400MHz, CDCl3): δ 8.66 (br, 1H), 8.48 
(d, J=1.84 Hz, 1H), 7.88 (m, 2H), 7.51 (m, 3H), 6.91 (d,d, J= 1.96 Hz, J= 8.4 Hz, 1H), 
8.86 (d, J= 8.4 Hz, 1H), 4.61 (m, J= 6.08 Hz, 1H), 3.20 (m, 2H), 2.74 (t, 2H), 6.64 (m, 
1H), 1.87 (m, 2H), 1.67 (m, 2H), 1.39 (d, J= 6.04 Hz, 6H). 
)-(2-isopropoxy-5-(piperidinn-4-yl)phenyl)pyrazine-2-carboxamide (63) :  
 
To a solution of 1 equivalent (200 mg, 0.4582 mmol) N-(2-isopropoxy-5-(1-
(2,2,2,-trifluoroacetyl)piperidine-4-yl)phenyl)pyrazine-2-carboxamide in methanol (20 
mL) and water (5 mL), 5.2 equivalents of potassium carbonate (328 mg, 2.382 mmol) was 
added. The reaction mixture was refluxed at 1000C for 2 hours. Methanol and water were 
evaporated off followed by dissolving the contents in dichloromethane. This solution was 
then washed with saturated sodium bicarbonate solution, brine, dried over sodium sulfate 
and concentrated to obtain pure N-(2-isopropoxy-5-(piperidinn-4-yl)phenyl)pyrazine-2-
carboxamide (152.5 mg, 97.75% yield) as a pale yellow solid. 1H NMR (400MHz, 
CDCl3): δ 10.37 (br, 1H), 9.49 (d, J= 1.44 Hz, 1H), 8.78 (d, J= 2.44 Hz, 1H),  8.61 (d,d, 
J= 1.52 Hz, J= 2.44 Hz, 1H), 8.51 (d, J= 2.08 Hz, 1H), 6.94 (d,d, J= 2.08 Hz, J= 8.44 Hz, 
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1H), 6.89 (d, J= 8.44 Hz, 1H), 4.57 (m, J= 6.08 Hz, 1H), 3.19 (m, 2H), 2.74 (t, 2H), 2.64 
(m, 1H), 1.86 (m, 2H), 1.64 (m, 2H), 1.41 (d, J= 6.04 Hz, 6H). 
1-Methyl-4-(4’-trifluoromethylphenoxy)benzene (28).  
 
In a 10 mL glass tube, 1 equivalent of p-cresol (480.57 mg, 4.444 mmol), 0.5 
equivalent of 4-trifluorobromobenzene (500 mg, 2.222 mmol), 0.1 equivalent of 
tetramethyl ethylene diamine (TMEDA) (51.59 mg, 0.444 mmol), 1 equivalent of 
potassium tert-butoxide (498.68 mg, 4.444 mmol) and 0.05 equivalent of copper iodide 
(70.45 mg, 0.222 mmol) were added with 1.5 mL DMF as the solvent. The glass tube was 
tightly closed with a cork and placed in the microwave. The temperature and time were set 
to 1250C and 25 minutes respectively. After 25 minutes, the contents were filtered through 
celite to remove the catalyst. The crude compound was purified by column 
chromatography on silica gel with hexane: ethyl acetate (40:1) as the solvent system. 1-
Methyl-4-(4’-trifluoromethylphenoxy)benzene was obtained as white shining crystals (522 
mg, 93.13% yield). 1H NMR (400MHz, CDCl3): δ 7.54 (m, 2H), 7.18 (m, 2H), 7 (m, 2H), 
6.94 (m, 2H), 2.35 (s, 1H). 
1-(bromomethyl)-4-(4’-(trifluoromethyl)phenoxy)benzene (40). 
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In a 50 mL three-necked round bottom flask, 0.8 equivalent of 1-Methyl-4-(4’-
trifluoromethylphenoxy)benzene (200 mg, 1.085 mmol) was dissolved in 4 mL carbon 
tetra chloride which was used as the solvent of this reaction. To this suspension, 1 
equivalent of N-bromosuccinimide (NBS) (242 mg, 1.3597 mmol) and 0.02 equivalent of 
azobisisobutyronitrile (AIBN) (6 mg, 0.03656 mmol) were added. This reaction mixture 
was refluxed for 2 hours under N2 protection on a pre-heated mantel at 81
0C – 820C. The 
solvent was evaporated and the crude compound was purified by column chromatography 
on silica gel using hexane: ethyl acetate (40:1) as the solvent system. 1-(bromomethyl)-4-
(4’-(trifluoromethyl)phenoxy)benzene was obtained as a pale yellow oil (150 mg, 51.16% 
yield). 1H NMR (400MHz, CDCl3): δ 7.57 (d, 2H), 7.39 (d, 2H), 7.05 (d, 2H), 6.95 (d, 
2H), 4.49 (s, 1H).  
1-methoxy-4-(p-tolyloxy)benzene (18): 
 
In a 50 mL three necked round bottom flask, 1 equivalent of p-cresol (1 g, 9.24 
mmol), 0.769 equivalents of 4-bromoanisole (1.328 g, 7.105 mmol), 0.846 equivalents of 
cesium carbonate (2.5 g, 7.817 mmol), and 0.0038 equivalents of copper bromide (7.8 mg, 
0.0351 mmol) were added. 1 mL of N-methylpyrolidone (NMP) was added to the above 
mixture. The reaction mixture was refluxed for 16 hours on a pre-heated mantel at 1600C. 
The reaction was quenched with acetonitrile (5 mL). The resulting suspension was filtered 
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through celite to remove the catalyst. The product was purified by column 
chromatography on silica gel with a hexyl: ethyl acetate (40:1) solvent system. Pure 1-
methoxy-4-(p-tolyloxy)benzene was obtained (1.65 g, 83.4% yield) as a pale yellow solid. 
1H NMR (400MHz, CDCl3): δ 7.10 (m, 2H), 6.96 (m, 2H), 6.86 (m, 4H), 6.94 (m, 2H), 
3.80 (s, 3H), 2.32 (s, 3H). 
1-methyl-4-phenoxybenzene (19): 
 
In a 50 mL three necked round bottom flask, 1 equivalent of p-cresol (1 g, 9.24 
mmol), 0.769 equivalents of 4-bromobenzene (1.115 g, 7.105 mmol), 0.846 equivalents of 
cesium carbonate (2.5 g, 7.817 mmol), and 0.0038 equivalents of copper bromide (7.8 mg, 
0.0351 mmol) were added. 1 mL of N-methylpyrolidone (NMP) was added to the above 
mixture. The reaction mixture was refluxed for 16 hours on a pre-heated mantel at 1600C. 
The reaction was quenched with acetonitrile (5 mL). The resulting suspension was filtered 
through celite to remove the catalyst. The product was purified by column 
chromatography on silica gel with a hexyl: ethyl acetate (40:1) solvent system. Pure 1-
methyl-4-phenoxybenzene was obtained (1.30 g, 76.8% yield) as a pale yellow solid. 1H 
NMR (400MHz, CDCl3): δ 7.29 (m, 2H), 7.12 (m, 2H), 7.04 (m, 1H), 6.97 (m, 2H), 6.90 
(m, 2H), 2.32 (s, 3H). 
4,4'-oxybis(methylbenzene) (25): 




In a 50 mL three necked round bottom flask, 1 equivalent of p-cresol (1 g, 9.24 
mmol), 0.769 equivalents of 4-bromotoluene (1.215 g, 7.105 mmol), 0.846 equivalents of 
cesium carbonate (2.5 g, 7.817 mmol), and 0.0038 equivalents of copper bromide (7.8 mg, 
0.0351 mmol) were added. 1 mL of N-methylpyrolidone (NMP) was added to the above 
mixture. The reaction mixture was refluxed for 16 hours on a pre-heated mantel at 1600C. 
The reaction was quenched with acetonitrile (5 mL). The resulting suspension was filtered 
through celite to remove the catalyst. The product was purified by column 
chromatography on silica gel with a hexyl: ethyl acetate (40:1) solvent system. Pure 4,4'-
oxybis(methylbenzene)  was obtained (1.01 g, 72% yield) as a pale yellow solid. 1H NMR 
(400MHz, CDCl3): δ 7.12 (d, J= 8.16 Hz, 4H), 6.82 (d, J= 8.52 Hz, 4H), 2.29 (s, 6H). 
1-chloro-4-(p-tolyloxy)benzene (24): 
 
In a 50 mL three necked round bottom flask, 1 equivalent of p-cresol (500 mg, 
4.62 mmol), 0.769 equivalents of 4-chlorobromobenzene (777.4 mg, 3.55 mmol), 0.846 
equivalents of cesium carbonate (1.2 g, 3.91 mmol), and 0.0038 equivalents of copper 
bromide (3.9 mg, 0.0175 mmol) were added. 1 mL of N-methylpyrolidone (NMP) was 
added to the above mixture. The reaction mixture was refluxed for 16 hours on a pre-
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heated mantel at 1600C. The reaction was quenched with acetonitrile (5 mL). The resulting 
suspension was filtered through celite to remove the catalyst. The product was purified by 
column chromatography on silica gel with a hexyl: ethyl acetate (40:1) solvent system. 
Pure 1-chloro-4-(p-tolyloxy)benzene  was obtained (551 mg, 62.05% yield) as a pale 
yellow solid. 1H NMR (400MHz, CDCl3): δ 7.29 (m, 2H), 7.17 (m, 2H), 6.89 (m, 4H), 
2.31 (s, 3H). 
1-methyl-4-(4-nitrophenoxy)benzene (31): 
 
In a 50 mL three necked round bottom flask, 1 equivalent of p-cresol (535.3 mg, 
4.95 mmol), 0.5 equivalents of 1-bromo-4-nitrobenzene (500 mg, 2.47 mmol), 0.1 
equivalents of TMEDA (57.5 mg, 0.495 mmol), 1 equivalent of potassium tertbutoxide 
(555.43 mg, 4.95 mmol), and 0.05 equivalents of copper iodide (78.54 mg, 0.247 mmol) 
were added. 3 mL of DMF was added to the above mixture. The reaction mixture was 
refluxed for 16 hours on a pre-heated mantel at 1250C. The resulting suspension was 
filtered through celite to remove the catalyst. The product was purified by column 
chromatography on silica gel with a hexyl: ethyl acetate (40:1) solvent system. Pure 1-
methyl-4-(4-nitrophenoxy)benzene was obtained (517 mg, 91.12% yield) as a yellow 
solid. 1H NMR (400MHz, CDCl3): δ 8.18 (m, 2H), 7.22 (m, 2H), 6.98 (m, 4H), 2.38 (s, 
3H). 
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6.1.2 Synthesis of Final Compounds: 
A. Phenyl substituted compounds: 
)-(2-Isopropoxy-5-(1-(4-(4-(trifluoromethyl)phenoxy)benzyl)piperidin-4-
yl)phenyl)benzamide (41). 









To a solution of 1 equivalent of N-(2-isopropoxy-5-(piperidinn-4-
yl)phenyl)benzamide (94 mg, 0.277 mmol)  in 5 mL DMF, 1.5 equivalents of potassium 
carbonate (57.57 mg, 0.4166 mmol) and catalytic amount of potassium iodide were added. 
This mixture was stirred at 00C on an ice-water bath for 15 minutes. This was followed by 
the addition of 1.2 equivalents of 1-(bromomethyl)-4-(4-
(trifluoromethyl)phenoxy)benzene (110.33 mg, 0.3332 mmol) dropwise over a period of 
five minutes. This reaction mixture was allowed to run over night from 00C to room 
temperature. DMF was evaporated and the contents were dissolved in dichloromethane. 
The crude compound was purified by column chromatography on silica gel with 
dichloromethane: methanol (100:1) as the solvent system with 1% NH4OH. The pure 
compound was obtained as pale yellow oil (85 mg, 52% yield). 1H NMR (400MHz, 
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CDCl3): δ 8.6 (br, 1H), 8.50 (d, J= 1.88 Hz, 1H), 7.88 (m, 2H), 7.49 (m, 5H), 7.39 (m, 
2H), 7.03 (m, 4H), 6.92 (d,d, J= 2.04 Hz, J= 8.40 Hz, 1H), 6.86 (d, J= 8.48 Hz, 1H), 4.59 
(m, J= 6.04 Hz, 1H), 3.56 (s, 2H), 3.04 (m, 2H), 2.54 (m, 1H), 2.11 (s, 2H), 1.86 (s, 4H), 
1.39 (d, J= 6.04 Hz, 6H). 13C NMR (400MHz, CDCl3): δ 164.93, 144.74, 135.39, 131.68, 
130.94, 128.84, 128.69, 127.81, 127.15, 127.11, 127.08, 127.04, 126.91, 121.43, 119.71, 
118.72, 117.79, 112.65, 71.62, 62.56, 54.23, 42.07, 33.36, 22.36. IR (Smart iTR diamond 
ATR, cm-1) 3421, 1672, 1325, 1246, 1105, 1064. MS m/z: 589. This compound was 
converted to the corresponding hydrochloride salt and a white powder was collected 
which had a melting point of 1590C - 1600C. 
)-(5-(1-(4-benzoylbenzyl)piperidin-4-yl)-2-isopropoxyphenyl)benzamide (67). 
                                              
To a solution of 1 equivalent of N-(2-isopropoxy-5-(piperidinn-4-
yl)phenyl)benzamide (70 mg, 0.2068 mmol)  in 5 mL DMF, 1.5 equivalents of potassium 
carbonate (42.81 mg, 0.3102 mmol) and catalytic amount of potassium iodide were added. 
This mixture was stirred at 00C on an ice-water bath for 15 minutes. This was followed by 
the addition of 1.2 equivalents of (4-(bromomethyl)phenyl)(phenyl)methanone (68.26 mg, 
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0.2481 mmol) drop wise over a period of five minutes. This reaction mixture was allowed 
to run over night from 00C to room temperature. DMF was evaporated and the contents 
were dissolved in dichloromethane. The crude compound was purified by column 
chromatography on silica gel with dichloromethane: methanol (100:1) as the solvent 
system with 1% NH4OH. The pure compound was obtained as pale yellow oil (71 mg, 
64.44% yield). 1H NMR (400MHz, CDCl3): δ 8.6 (br, 1H), 8.51 (d, J= 2.0 Hz, 1H), 7.90 
(m, 2H), 7.81 (m, 4H), 7.57 (m, 2H), 7.49 (m, 6H), 6.93 (d,d, J= 2.12 Hz, J= 8.40 Hz, 1H), 
6.86 (d, J= 8.48 Hz, 1H), 4.59 (m, J= 6.08 Hz, 1H), 3.63 (s, 2H), 3.03 (m, 2H), 2.54 (m, 
1H), 2.14 (s, 2H), 1.86 (s, 4H), 1.39 (d, J= 6.04 Hz, 6H). 13C NMR (400MHz, CDCl3): δ 
196.53, 164.91, 144.71, 137.84, 136.36, 135.40, 132.26, 131.66, 130.18, 130.03, 128.90, 
128.83, 128.70, 128.24, 126.91, 121.46, 118.67, 112.62, 71.61, 63.03, 54.46, 42.12, 33.55, 
22.37. IR (Smart iTR diamond ATR, cm-1) 3410, 1656, 1531, 1276. MS m/z: 533. This 
compound was converted to the corresponding hydrochloride salt and a white powder was 
collected which had a melting point of 1160C - 1170C. 
)-(5-(1-((2'-cyano-[1,1'-biphenyl]-4-yl)methyl)piperidin-4-yl)-2-
isopropoxyphenyl)benzamide (68). 
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To a solution of 1 equivalent of N-(2-isopropoxy-5-(piperidinn-4-
yl)phenyl)benzamide (70 mg, 0.2068 mmol)  in 5 mL DMF, 1.5 equivalents of potassium 
carbonate (42.81 mg, 0.3102 mmol) and catalytic amount of potassium iodide were added. 
This mixture was stirred at 00C on an ice-water bath for 15 minutes. This was followed by 
the addition of 1.2 equivalents of 4'-(bromomethyl)-[1,1'-biphenyl]-2-carbonitrile (67.51 
mg, 0.2481 mmol) dropwise over a period of five minutes. This reaction mixture was 
allowed to run over night from 00C to room temperature. DMF was evaporated and the 
contents were dissolved in dichloromethane. The crude compound was purified by column 
chromatography on silica gel with dichloromethane: methanol (100:1) as the solvent 
system with 1% NH4OH. The pure compound was obtained as pale yellow oil (52 mg, 
47.46% yield). 1H NMR (400MHz, CDCl3): δ 8.6 (br, 1H), 8.50 (d, J= 1.96 Hz, 1H), 7.88 
(m, 2H), 7.76 (m, 1H), 7.64 (t, J= 7.76 Hz, 1H), 7.52 (m, 8H), 7.42 (t, J= 7.64 Hz, 1H), 
6.93 (d,d, J= 2.08 Hz, J= 8.40 Hz, 1H), 6.86 (d, J= 8.48 Hz, 1H), 4.58 (m, J= 6.0 Hz, 1H), 
3.64 (s, 2H), 3.07 (m, 2H), 2.55 (m, 1H), 2.16 (s, 2H), 1.87 (s, 4H), 1.40 (d, J= 6.04 Hz, 
6H). 13C NMR (400MHz, CDCl3): δ 164.90, 145.38, 144.71, 135.42, 133.77, 132.78, 
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131.64, 130.10, 129.55, 129.43, 128.82, 128.66, 125.54, 127.40, 126.91, 121.43, 118.81, 
118.76, 112.64, 111.21, 71.55, 62.94, 54.40, 42.11, 33.48, 22.37. IR (Smart iTR diamond 
ATR, cm-1) 3412, 2224, 1668, 1325, 1249. MS m/z: 530. This compound was converted to 
the corresponding hydrochloride salt and a white powder was collected which had a 
melting point of 1280C - 1290C. 
)-(5-(1-([1,1'-biphenyl]-4-ylmethyl)piperidin-4-yl)-2-isopropoxyphenyl)benzamide 
(73).  
                                              
To a solution of 1 equivalent of N-(2-isopropoxy-5-(piperidinn-4-
yl)phenyl)benzamide (80 mg, 0.236 mmol)  in 5 mL DMF, 1.5 equivalents of potassium 
carbonate (44.4 mg, 0.322 mmol) and catalytic amount of potassium iodide were added. 
This mixture was stirred at 00C on an ice-water bath for 15 minutes. This was followed by 
the addition of 1.2 equivalents of 4-(chloromethyl)-1,1'-biphenyl (52.08 mg, 0.257 mmol) 
dropwise over a period of five minutes. This reaction mixture was allowed to run over 
night from 00C to room temperature. DMF was evaporated and the contents were 
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dissolved in dichloromethane. The crude compound was purified by column 
chromatography on silica gel with dichloromethane: methanol (100:1) as the solvent 
system with 1% NH4OH. The pure compound was obtained as pale yellow oil (52 mg, 
47.46% yield).1H NMR (400MHz, CDCl3): δ 8.65 (br, 1H), 8.50 (d, J= 2.0 Hz, 1H), 7.88 
(m, 2H), 7.55 (m, 7H), 7.43 (m, 4H), 7.33 (m, 1H), 6.92 (d,d, J= 2.08 Hz, J= 8.40 Hz, 1H), 
6.85 (d, J= 8.48 Hz, 1H), 4.58 (m, J= 6.04 Hz, 1H), 3.61 (s, 2H), 3.07 (m, 2H), 2.53 (m, 
1H), 2.14 (s, 2H), 1.86 (s, 4H), 1.39 (d, J= 6.04 Hz, 6H). 13C NMR (400MHz, CDCl3): δ 
164.90, 144.71, 135.43, 129.70, 128.82, 128.72, 128.68, 127.09, 126.99, 126.92, 121.41, 
118.77, 112.65, 71.61, 54.35, 42.19, 33.52, 22.37. IR (Smart iTR diamond ATR, cm-1) 
3412, 1666, 1248, 1074. MS m/z: 505. This compound was converted to the 
corresponding hydrochloride salt and a white powder was collected which had a melting 
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To a solution of 1 equivalent of N-(2-isopropoxy-5-(piperidinn-4-
yl)phenyl)benzamide (80 mg, 0.236 mmol)  in 5 mL methanol, 1.5 equivalents of pyridine 
(25.44 mg, d. 0.9819 g/mL, 0.025 mL, 0.322 mmol) was added. This mixture was stirred 
at 600C on a pre-heated mantel for 15 minutes. This was followed by the addition of 1.2 
equivalents of 2-(bromomethyl)-1,1'-biphenyl (63.5 mg, 0.257 mmol) drop wise over a 
period of five minutes. The reaction mixture was refluxed overnight at 700C. Methanol 
was evaporated and the contents were dissolved in dichloromethane. Pyridine was 
removed by washing with 20 mL 1N HCl twice followed by extraction of the organic 
layer with dichloromethane. The crude compound was purified by column 
chromatography on silica gel with dichloromethane: methanol (100:1) as the solvent 
system with 1% NH4OH. The pure compound was obtained as pale yellow oil (56 mg, 
46.97%). 1H NMR (400MHz, CDCl3): δ 8.65 (br, 1H), 8.46 (d, J= 1.92 Hz, 1H), 7.88 (m, 
2H), 7.53 (m, 4H), 7.35 (m, 8H), 6.89 (d,d, J= 1.84 Hz, J= 8.40 Hz, 1H), 6.84 (d, J= 8.44 
Hz, 1H), 4.57 (m, J= 6.04 Hz, 1H), 3.42 (s, 2H), 2.92 (m, 2H), 2.44 (m, 1H), 1.95 (m, 2H), 
1.77 (s, 4H), 1.38 (d, J= 6.08 Hz, 6H). 13C NMR (400MHz, CDCl3): δ 164.90, 144.65, 
142.54, 141.62, 139.67, 136.35, 135.44, 131.63, 129.96, 129.86, 129.59, 128.82, 128.67, 
127.85, 127.13, 127.09, 126.91, 126.78, 126.55, 121.48, 118.66, 114.76, 112.61, 71.62, 
60.11, 54.10, 42.21, 33.73, 22.38. IR (Smart iTR diamond ATR, cm-1) 3415, 1668, 1247, 
1073. MS m/z: 505. This compound was converted to the corresponding hydrochloride 
salt and a white powder was collected which had a melting point of 1040C - 1050C. 
)-(2-isopropoxy-5-(1-(3-phenoxybenzyl)piperidin-4-yl)phenyl)benzamide (74). 
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To a solution of 1 equivalent of N-(2-isopropoxy-5-(piperidinn-4-
yl)phenyl)benzamide (80 mg, 0.236 mmol)  in 5 mL methanol, 1.5 equivalents of pyridine 
(25.44 mg, d. 0.9819 g/mL, 0.025 mL, 0.322 mmol) was added. This mixture was stirred 
at 600C on a pre-heated mantel for 15 minutes. This was followed by the addition of 1.2 
equivalents of 1-(chloromethyl)-3-phenoxybenzene (56.2 mg, 0.257 mmol) drop wise over 
a period of five minutes. This reaction mixture was refluxed overnight at 700C. Methanol 
was evaporated and the contents were dissolved in dichloromethane. Pyridine was 
removed by washing with 20 mL 1N HCl twice followed by extraction of the organic 
layer with dichloromethane. The crude compound was purified by column 
chromatography on silica gel with dichloromethane: methanol (100:1) as the solvent 
system with 1% NH4OH. The pure compound was obtained as pale yellow oil (51 mg, 
42.7%). 1H NMR (400MHz, CDCl3): δ 8.65 (br, 1H), 8.48 (d, J= 1.86 Hz, 1H), 7.86 (m, 
2H), 7.55 (m, 3H), 7.31 (m, 3H), 7.03 (m, 4H), 6.90 (d,d, J= 2.04 Hz, J= 8.40 Hz, 1H), 
6.85 (d, J= 8.44 Hz, 1H), 4.58 (m, J= 6.04 Hz, 1H), 3.54 (s, 2H), 3.01 (m, 2H), 2.51 (m, 
1H), 2.10 (m, 2H), 1.83 (s, 4H), 1.85 (d, J= 6.08 Hz, 6H). 13C NMR (400MHz, CDCl3): δ 
164.90, 157.15, 135.43, 131.64, 129.71, 128.82, 128.13, 126.92, 123.09, 121.37, 119.74, 
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119.08, 118.84, 118.78, 112.65, 71.61, 63.02, 54.29, 42.12, 33.05, 22.38. IR (Smart iTR 
diamond ATR, cm-1) 3416, 1667, 1253, 1072. MS m/z:  521. This compound was 
converted to the corresponding hydrochloride salt and a white powder was collected 
which had a melting point of 940C - 950C. 
)-(5-(1-([1,1'-biphenyl]-3-ylmethyl)piperidin-4-yl)-2-isopropoxyphenyl)benzamide 
(71). 








To a solution of 1 equivalent of N-(2-isopropoxy-5-(piperidinn-4-
yl)phenyl)benzamide (50 mg, 0.1477 mmol)  in 5 mL methanol, 1.5 equivalents of 
pyridine (17.50 mg, d. 0.9819 g/mL, 0.017 mL, 0.2216 mmol) was added. This mixture 
was stirred at 600C on a pre-heated mantel for 15 minutes. This was followed by the 
addition of 1.2 equivalents of 3-(bromomethyl)-1,1'-biphenyl (43.79, 0.1772 mmol) 
dropwise over a period of five minutes. This reaction mixture was refluxed overnight at 
700C. Methanol was evaporated and the contents were dissolved in dichloromethane. 
Pyridine was removed by washing with 20 mL 1N HCl twice followed by extraction of the 
organic layer with dichloromethane. The crude compound was purified by column 
chromatography on silica gel with dichloromethane: methanol (100:1) as the solvent 
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system with 1% NH4OH. The pure compound was obtained as pale yellow oil (37 mg, 
49.63% yield). 1H NMR (400MHz, CDCl3): δ 8.6 (br, 1H), 8.49 (d, J= 1.96 Hz, 1H), 7.87 
(m, 2H), 7.61 (m, 3H), 7.53 (m, 4H), 7.42 (m, 3H), 7.34 (m, 2H), 6.92 (d,d, J= 2.12 Hz, J= 
8.44 Hz, 1H), 6.85 (d, J= 8.44 Hz, 1H), 4.60 (m, J= 6.0 Hz, 1H), 3.63 (s, 2H), 3.06 (m, 
2H), 2.51 (m, 1H), 2.13 (s, 2H), 1.83 (s, 4H), 1.38 (d, J= 6.04 Hz, 6H). ). 13C NMR 
(400MHz, CDCl3): δ 164.87, 144.68, 141.20, 141.14, 139.41, 138.86, 135.41, 131.63, 
128.81, 128.70, 128.66, 128.63, 128.22, 128.02, 127.79, 127.23, 127.18, 126.89, 125.86, 
121.43, 118.74, 112.64, 71.59, 63.43, 54.35, 42.17, 33.50, 22.67. IR (Smart iTR diamond 
ATR, cm-1) 3416, 1667, 1249, 1074. MS m/z: 505. This compound was converted to the 
corresponding hydrochloride salt and a white powder was collected which had a melting 
point of 1110C - 1120C. 
B. Pyrazine substituted compounds: 
)-(2-isopropoxy-5-(1-(4-(4-(trifluoromethyl)phenoxy)benzyl)piperidin-4-
yl)phenyl)pyrazine-2-carboxamide (II-17). 
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To a solution of 1 equivalent of N-(2-isopropoxy-5-(piperidinn-4-
yl)phenyl)pyrazine-2-carboxamide (70 mg, 0.2056 mmol)  in 5 mL methanol, 1.5 
equivalents of pyridine (24.37 mg, d. 0.9819 g/mL, 0.024 mL, 0.3084 mmol) was added. 
This mixture was stirred at 600C on a pre-heated mantel for 15 minutes. This was followed 
by the addition of 1.2 equivalents of 1-(bromomethyl)-4-(4-
(trifluoromethyl)phenoxy)benzene (81.68 mg, 0.2467 mmol) dropwise over a period of 
five minutes. This reaction mixture was refluxed overnight at 700C. Methanol was 
evaporated and the contents were dissolved in dichloromethane. Pyridine was removed by 
washing with 20 mL 1N HCl twice followed by extraction of the organic layer with 
dichloromethane. The crude compound was purified by column chromatography on silica 
gel with dichloromethane: methanol (100:1) as the solvent system with 1% NH4OH. The 
pure compound was obtained as pale yellow oil (43 mg, 35.42%). 1H NMR (400MHz, 
CDCl3): δ 10.37 (br, 1H), 9.50 (d, J= 1.44 Hz, 1H), 8.78 (d, J= 2.44 Hz, 1H), 8.60 (d,d, J= 
1.52 Hz, J= 2.4 Hz, 1H), 8.53 (d, J= 2.04 Hz, 1H), 7.57 (d, J= 8.6 Hz, 2H), 7.39 (d, J= 
8.24 Hz) 2H), 7.03 (m, 4H), 6.95 (d,d, J= 2.08 Hz, J= 8.40 Hz, 1H), 6.89 (d, J= 8.44 Hz, 
1H), 4.56 (m, J= 6.04 Hz, 1H), 3.56 (s, 2H), 3.04 (m, 2H), 2.54 (m, 1H), 2.12 (s, 2H), 1.86 
(s, 4H), 1.39 (d, J= 6.04 Hz, 6H). 13C NMR (400MHz, CDCl3): δ 160.51, 147.81, 145.42, 
145.18, 144.58, 142.64, 130.84, 128.29, 127.12, 127.08, 122.18, 119.71, 118.76, 117.76, 
113.58, 72.14, 63.03, 54.31, 42.12, 33.55, 22.37. IR (Smart iTR diamond ATR, cm-1) 
3343, 1691, 1228, 1050. MS m/z: 591. This compound was converted to the 
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corresponding hydrochloride salt and a white powder was collected which had a melting 
point of 2100C - 2120C 
)-(5-(1-(4-benzoylbenzyl)piperidin-4-yl)-2-isopropoxyphenyl)pyrazine-2-
carboxamide (64). 
                                            
To a solution of 1 equivalent of N-(2-isopropoxy-5-(piperidinn-4-
yl)phenyl)pyrazine-2-carboxamide (55 mg, 0.1615 mmol)  in 5 mL DMF, 1.5 equivalents 
of potassium carbonate (33.43mg, 0.2422 mmol) was added. This mixture was stirred at 
00C on an ice-water bath for 15 minutes. This was followed by the addition of 1.2 
equivalents of (4-(bromomethyl)phenyl)(phenyl)methanone (53.32 mg, 0.1938 mmol) 
drop wise over a period of five minutes. This reaction mixture was allowed to run over 
night from 00C to room temperature. DMF was evaporated and the contents were 
dissolved in dichloromethane. The crude compound was purified by column 
chromatography on silica gel with dichloromethane: methanol (100:1) as the solvent 
system with 1% NH4OH. The pure compound was obtained as pale yellow oil (58 mg, 
67.14%). 1H NMR (400MHz, CDCl3): δ 10.38 (br, 1H), 9.49 (d, J= 1.44 Hz, 1H), 8.78 (d, 
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J= 2.44 Hz, 1H), 8.61 (d,d, J= 1.48 Hz, J= 2.4 Hz, 1H), 8.53 (d, J= 2.08 Hz, 1H), 7.81 (m, 
5H), 7.56 (m, 1H), 7.49 (m, 4H), 6.95 (d,d, J= 2.08 Hz, J= 8.40 Hz, 1H), 6.89 (d, J= 8.44 
Hz, 1H), 4.57 (m, J= 6.08 Hz, 1H), 3.62 (s, 2H), 3.02 (m, 2H), 2.53 (m, 1H), 2.14 (s, 2H), 
1.85 (s, 4H), 1.41 (d, J= 6.04 Hz, 6H). 13C NMR (400MHz, CDCl3): δ 160.47, 144.71, 
137.84, 136.36, 135.40, 132.26, 131.66, 130.18, 130.03, 128.90, 128.83, 128.70, 128.24, 
126.91, 121.46, 118.67, 112.62, 71.61, 63.03, 54.46, 42.12, 33.55, 22.37. IR(Smart iTR 
diamond ATR, cm-1) 3368, 1681, 1635, 1223, 1051. MS m/z: 535. This compound was 
converted to the corresponding hydrochloride salt and a white powder was collected 
which had a melting point of 1300C - 1310C. 
 )-(5-(1-((2'-cyano-[1,1'-biphenyl]-4-yl)methyl)piperidin-4-yl)-2-
isopropoxyphenyl)pyrazine-2-carboxamide (II-3). 
                                         
To a solution of 1 equivalent of N-(2-isopropoxy-5-(piperidinn-4-
yl)phenyl)pyrazine-2-carboxamide (73 mg, 0.2144 mmol)  in 5 mL methanol, 1.5 
equivalents of pyridine (44.38 mg, d. 0.9819 g/mL, 0.044 mL, 0.3216 mmol) was added. 
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This mixture was stirred at 600C on a pre-heated mantel for 15 minutes. This was followed 
by the addition of 1.2 equivalents of 4'-(bromomethyl)-[1,1'-biphenyl]-2-carbonitrile 
(70.05 mg, 0.2573 mmol) dropwise over a period of five minutes. This reaction mixture 
was refluxed overnight at 700C. Methanol was evaporated and the contents were dissolved 
in dichloromethane. Pyridine was removed by washing with 20 mL 1N HCl twice 
followed by extraction of the organic layer with dichloromethane. The crude compound 
was purified by column chromatography on silica gel with dichloromethane: methanol 
(100:1) as the solvent system with 1% NH4OH. The pure compound was obtained as a 
pale yellow oil (40 mg, 35.08%). 1H NMR (400MHz, CDCl3): δ 10.37 (br, 1H), 9.50 (d, 
J= 1.44 Hz, 1H), 8.77 (d, J= 2.40 Hz, 1H), 8.61 (d,d, J= 1.56 Hz, J= 2.36 Hz, 1H), 8.53 (d, 
J= 2.04 Hz, 1H), 7.76 (m, 1H), 7.64 (t, J= 7.68 Hz, 1H), 7.50 (m, 5H), 7.42 (t, J= 7.64 Hz, 
1H), 6.96 (d,d, J= 2.04 Hz, J= 8.40 Hz, 1H), 6.89 (d, J= 8.44 Hz, 1H), 4.56 (m, J= 6.08 
Hz, 1H), 3.61 (s, 2H), 3.06 (m, 2H), 2.55 (m, 1H), 2.13 (s, 2H), 1.86 (s, 4H), 1.42 (d, J= 
6.04 Hz, 6H). 13C NMR (400MHz, CDCl3): δ 160.47, 147.16, 145.39, 145.20, 144.59, 
142.63, 133.78, 132.77, 130.11, 129.46, 128.63, 128.26, 127.38, 122.19, 118.79, 113.58, 
111.25, 72.12, 54.46, 33.61, 22.31. IR(Smart iTR diamond ATR, cm-1) 3350, 1681, 1250, 
1047. MS m/z: 532. This compound was converted to the corresponding hydrochloride 
salt and a while powder was collected which had a melting point of 1520C - 1530C. 
)-(5-(1-([1,1'-biphenyl]-4-ylmethyl)piperidin-4-yl)-2-isopropoxyphenyl)pyrazine-2-
carboxamide (II-14). 
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To a solution of 1 equivalent of N-(2-isopropoxy-5-(piperidinn-4-
yl)phenyl)pyrazine-2-carboxamide (70 mg, 0.2056 mmol)  in 5 mL methanol, 1.5 
equivalents of pyridine (24.36 mg, d. 0.9819 g/mL, 0.024 mL, 0.3084 mmol) was added. 
This mixture was stirred at 600C on a pre-heated mantel for 15 minutes. This was followed 
by the addition of 1.2 equivalents of 4-(chloromethyl)-1,1'-biphenyl (50 mg, 0.2467 
mmol) dropwise over a period of five minutes. This reaction mixture was refluxed 
overnight at 700C. Methanol was evaporated and the contents were dissolved in 
dichloromethane. Pyridine was removed by washing with 20 mL 1N HCl twice followed 
by extraction of the organic layer with dichloromethane. The crude compound was 
purified by column chromatography on silica gel with dichloromethane: methanol (100:1) 
as the solvent system with 1% NH4OH. The pure compound was obtained as a pale yellow 
oil (49 mg, 47.11%). 1H NMR (400MHz, CDCl3): δ 10.37 (br, 1H), 9.50 (d, J= 1.44 Hz, 
1H), 8.77 (d, J= 2.44 Hz, 1H), 8.60 (d,d, J= 1.52 Hz, J= 2.36 Hz, 1H), 8.52 (d, J= 2.08 Hz, 
1H), 7.59 (m, 4H), 7.44 (m, 4H), 7.32 (m, 1H), 6.96 (d,d, J= 2.08 Hz, J= 8.40 Hz, 1H), 
6.88 (d, J= 8.44 Hz, 1H), 4.55 (m, J= 6.0 Hz, 1H), 3.61 (s, 2H), 3.05 (m, 2H), 2.54 (m, 
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1H), 2.13 (s, 2H), 1.86 (s, 4H), 1.41 (d, J= 6.04 Hz, 6H). 13C NMR (400MHz, CDCl3): δ 
160.47, 147.15, 145.38, 145.18, 144.58, 142.62, 141.06, 139.94, 129.65, 128.71, 128.25, 
127.11, 127.08, 126.96, 122.15, 118.79, 113.57, 72.11, 63.07, 54.36, 42.20, 33.55, 22.30. 
IR(Smart iTR diamond ATR, cm-1) 3357, 1683, 1255, 1047. MS m/z: 507. This 
compound was converted to the corresponding hydrochloride salt and a white powder was 
collected which had a melting point of 2090C - 2100C. 
)-(5-(1-([1,1'-biphenyl]-2-ylmethyl)piperidin-4-yl)-2-isopropoxyphenyl)pyrazine-2-
carboxamide (II-10). 
                                              
To a solution of 1 equivalent of N-(2-isopropoxy-5-(piperidinn-4-
yl)phenyl)pyrazine-2-carboxamide (70 mg, 0.2056 mmol)  in 5 mL methanol, 1.5 
equivalents of pyridine (24.36 mg, d. 0.9819 g/mL, 0.024 mL, 0.3084 mmol) was added. 
This mixture was stirred at 600C on a pre-heated mantel for 15 minutes. This was followed 
by the addition of 1.2 equivalents of 2-(bromomethyl)-1,1'-biphenyl (60.96 mg, 0.2467 
mmol) dropwise over a period of five minutes. This reaction mixture was refluxed 
overnight at 700C. Methanol was evaporated and the contents were dissolved in 
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dichloromethane. Pyridine was removed by washing with 20 mL 1N HCl twice followed 
by extraction of the organic layer with dichloromethane. The crude compound was 
purified by column chromatography on silica gel with dichloromethane: methanol (100:1) 
as the solvent system with 1% NH4OH. The pure compound was obtained as a pale yellow 
oil (65 mg, 62.39%). 1H NMR (400MHz, CDCl3): δ 10.37 (br, 1H), 9.50 (d, J= 1.44 Hz, 
1H), 8.78 (d, J= 2.44 Hz, 1H), 8.60 (d,d, J= 1.52 Hz, J= 2.44 Hz, 1H), 8.50 (d, J= 1.96 Hz, 
1H), 7.63 (m, 1H), 7.36 (m, 8H), 6.93 (d,d, J= 2.0 Hz, J= 8.40 Hz, 1H), 6.88 (d, J= 8.48 
Hz, 1H), 4.57 (m, J= 6.04 Hz, 1H), 3.47 (s, 2H), 2.94 (m, 2H), 2.54 (m, 1H), 1.98 (m, 2H), 
1.78 (s, 4H), 1.41 (d, J= 6.04 Hz, 6H). 13C NMR (400MHz, CDCl3): δ 160.47, 147.15, 
145.34, 145.17, 144.56, 142.63, 142.56, 141.57, 139.72, 129.99, 129.90, 129.58, 128.22, 
127.88, 127.18, 126.82, 126.65, 122.18, 118.69, 113.54, 72.10, 60.03, 54.06, 42.12, 33.63, 
22.30. IR(Smart iTR diamond ATR, cm-1) 3350, 1683, 1256, 1074. MS m/z: 507. This 
compound was converted to the corresponding hydrochloride salt and a white powder was 
collected which had a melting point of 1710C - 1720C. 
)-(2-isopropoxy-5-(1-(3-phenoxybenzyl)piperidin-4-yl)phenyl)pyrazine-2-
carboxamide (II-11). 
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To a solution of 1 equivalent of N-(2-isopropoxy-5-(piperidinn-4-
yl)phenyl)pyrazine-2-carboxamide (70 mg, 0.2056 mmol)  in 5 mL methanol, 1.5 
equivalents of pyridine (24.36 mg, d. 0.9819 g/mL, 0.024 mL, 0.3084 mmol) was added. 
This mixture was stirred at 600C on a pre-heated mantel for 15 minutes. This was followed 
by the addition of 1.2 equivalents of 1-(chloromethyl)-3-phenoxybenzene (53.95 mg, 
0.2467 mmol) dropwise over a period of five minutes. This reaction mixture was refluxed 
overnight at 700C. Methanol was evaporated and the contents were dissolved in 
dichloromethane. Pyridine was removed by washing with 20 mL 1N HCl twice followed 
by extraction of the organic layer with dichloromethane. The crude compound was 
purified by column chromatography on silica gel with dichloromethane: methanol (100:1) 
as the solvent system with 1% NH4OH. The pure compound was obtained as a pale yellow 
oil (74 mg, 68.86%). 1H NMR (400MHz, CDCl3): δ 10.37 (br, 1H), 9.49 (d, J= 1.24 Hz, 
1H), 8.77 (d, J= 2.40 Hz, 1H), 8.60 (d,d, J= 1.52 Hz, J= 2.32 Hz, 1H), 8.50 (d, J= 2.04 Hz, 
1H), 7.31 (m, 3H), 7.09 (m, 5H), 7.00 (d,d, J= 2.00 Hz, J= 8.36 Hz, 1H), 6.94 (d, J= 8.44 
Hz, 1H), 4.58 (m, J= 6.04 Hz, 1H), 3.57 (s, 2H), 3.04 (m, 2H), 2.53 (m, 1H), 2.13 (s, 2H), 
1.85 (s, 4H), 1.41 (d, J= 6.08 Hz, 6H). 13C NMR (400MHz, CDCl3): δ 160.47, 147.15, 
145.41, 145.18, 144.57, 142.63, 141.15, 129.71, 129.53, 128.23, 128.14, 126.82, 123.13, 
122.08, 119.80, 118.84, 118.80, 113.59, 72.11, 63.44, 54.19, 42.20, 33.51, 22.29. 
IR(Smart iTR diamond ATR, cm-1) 3357, 1683, 1255, 1047. MS m/z: 523. This 
compound was converted to the corresponding hydrochloride salt and a white powder was 
collected which had a melting point of 1240C - 1250C. 
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)-(5-(1-([1,1'-biphenyl]-3-ylmethyl)piperidin-4-yl)-2-isopropoxyphenyl)pyrazine-2-
carboxamide (II-15).  
                                           
To a solution of 1 equivalent of N-(2-isopropoxy-5-(piperidinn-4-
yl)phenyl)pyrazine-2-carboxamide (70 mg, 0.2056 mmol)  in 5 mL methanol, 1.5 
equivalents of pyridine (24.36 mg, d. 0.9819 g/mL, 0.024 mL, 0.3084 mmol) was added. 
This mixture was stirred at 600C on a pre-heated mantel for 15 minutes. This was followed 
by the addition of 1.2 equivalents of 3-(bromomethyl)-1,1'-biphenyl (60.98 mg, 0.2467 
mmol) dropwise over a period of five minutes. This reaction mixture was refluxed 
overnight at 700C. Methanol was evaporated and the contents were dissolved in 
dichloromethane. Pyridine was removed by washing with 20 mL 1N HCl twice followed 
by extraction of the organic layer with dichloromethane. The crude compound was 
purified by column chromatography on silica gel with dichloromethane: methanol (100:1) 
as the solvent system with 1% NH4OH. The pure compound was obtained as a pale yellow 
oil (45 mg, 44% yield). 1H NMR (400MHz, CDCl3): δ 10.36 (br, 1H), 9.49 (d, J= 1.44 
Hz, 1H), 8.77 (d, J= 2.44 Hz, 1H), 8.60 (d,d, J= 1.52 Hz, J= 2.36 Hz, 1H), 8.51 (d, J= 2.08 
Hz, 1H), 7.62 (m, 3H), 7.35 (m, 6H), 6.96 (d,d, J= 2.12 Hz, J= 8.44 Hz, 1H), 6.88 (d, J= 
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8.48 Hz, 1H), 4.54 (m, J= 6.04 Hz, 1H), 3.63 (s, 2H), 3.07 (m, 2H), 2.54 (m, 1H), 2.13 (s, 
2H), 1.85 (s, 4H), 1.41 (d, J= 6.08 Hz, 6H). 13C NMR (400MHz, CDCl3): δ 160.47, 
147.15, 145.38, 145.18, 144.57, 142.63, 141.23, 141.17, 139.59, 128.71, 128.65, 128.24, 
128.04, 127.25, 127.21, 122.16, 118.80, 113.57, 72.11, 63.46, 54.35, 42.19, 33.53, 22.30. 
IR (Smart iTR diamond ATR, cm-1) 3350, 1680, 1250, 1047. MS m/z: 507. This 
compound was converted to hydrochloride salt and a white powder was collected which 
had a melting point of 1220C to 1230C. 
6.2 Biological Screening:  
6.2.1Calcium Mobilization Assay: 
The cell line used for this assay was MOLT-4. The drug solutions were prepared in 
varying concentrations. The assay buffer which comprised of 25 mL HBBS and 0.5 mL 
HEPES was used to prepare the drug dilutions. 50 µL of drug solutions was added to each 
well. This was followed by the addition of MOLT-4 cells which were plated in a 
concentration of 80 µL per well. The cells along with the drug were incubated for 60 
minutes at 370C. The reaction buffer which comprised of 5 mL of assay buffer, 100 µL 
probenecid, and 40 µL Fluo-4 dye was prepared. 50 µL of the reaction buffer was added 
to the wells followed by incubation for 60 minutes at 370C. 
The stock solution of the agonist RANTES was prepared by adding 25 µL of the 
RANTES stock solution and 2.475 mL assay buffer. The RANTES solution was added to 
all wells except the blank cells, to which only assay buffer was added. The Flex station 
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was used to add RANTES and assay buffer to the wells. The fluorescence emission signal 
was recorded by the Flex station. The software Prism was used to obtain the IC50 values of 
the antagonists.  
6.2.2 Anti-proliferation Assay: 
A. Preparation of cells: 
The CCR5 antagonists were tested on two cell lines. These were PC-3 and M12 
cell lines which are prostate cancer cell lines. The cells were incubated at 370C and 5% 
CO2. The media which was used to grow the cells contained RPMI1640 (500 mL), 1% L-
glutamine, 0.1% ITS (5 µg/mL insulin, 5 µg/mL transferin, 5 µg/mL selenium), 0.1% 
gentamycin and 10% fetal bovine serum (FBS). The media used for M12 cell lines 
contained only 5% FBS and not 10% FBS. After 24 hours of incubation of the M12 cells, 
the media was replaced with serum free media containing 0.1% epidermal growth factor 
(EGF).  
B. Anti-Proliferation Assay protocol:  
On day 1, both cell lines were plated in 96 well plates. The cells were plated such 
that 1000 cells would be present in each well. For each cell line, their respective media 
was used to plate them in concentrations of 100 µL per well. This was followed by 
incubation of the cells along with their media for 24 hours. On day 2, after 24 hours, the 
drug solutions were added to each well. The drug solutions were prepared in phosphate 
buffer solution (PBS). The negative/solvent control included cells with only PBS and 
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DMSO. The percentage of DMSO used was the amount that was present in the highest 
concentration of drug tested. 50 µL of drug solution was added to each well. The cells 
were incubated with the drug solution for 72 hours. On day 5, the media, PBS and drug 
solutions were removed from the plate. This was followed by the addition of 100 µL of 
serum free media with 10% of anti-proliferative reagent WST-1. This was incubated for 3 
hours. The absorbance was then measured at 450 nM on Flex station 3.The software Prism 
was used to obtain the IC50 values of the drugs.                                                                                                       
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7. Conclusion: 
The constant increase in the number of prostate cancer cases in men as well as rise 
in mortality due to prostate cancer metastasis necessitates the development of new 
approaches in the treatment of prostate cancer. Inflammation has been closely associated 
in the etiology of prostate cancer. Analysis of the inflammatory network in prostate cancer 
emphasized the role of chemokines and chemokine receptors in the progression of cancer. 
The chemokine receptor CCR5 and its endogenous ligand CCL5 (RANTES) was found to 
be overexpressed in prostate cancer cells. This was followed by the discovery that CCR5 
antagonists were capable of inhibiting proliferation of prostate cancer cell lines.28 
The chemokine receptor CCR5 was subsequently identified to play a critical role 
in the entry process of HIV in to the host cell. CCR5 served as a co-receptor along with 
the cell surface CD4 receptor for the entry of HIV. It was observed that the gp120 of the 
viral envelope interacted with the extracellular loop 2 of the CCR5 receptor. With the 
constantly increasing number of cases of AIDS worldwide, there is a need for novel 
therapeutic approaches. This led to the discovery of CCR5 antagonists that were capable 
of blocking the receptor and preventing the interaction between the virus and CCR5.  
Due to the implication of CCR5 in various diseases, it served as a novel 
therapeutic target. Fourteen novel CCR5 antagonists were synthesized and their anti-
proliferative activity was explored against prostate cancer cell lines PC-3 and M12. 
Another assay that was performed to evaluate the CCR5 antagonists was the calcium 
mobilization assay. The synthesis of the CCR5 antagonists followed the synthetic route 
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used to synthesize the previous batch of compounds by our lab. Fourteen such compounds 
were synthesized and their biological screening was carried out. 
The anti-proliferative data for PC-3 and M12 showed different results. Compound 
19 showed the greatest anti-proliferative activity in the PC-3 cell line. However, it showed 
only moderate activity in the M12 cell line. Compounds 14 and 24 could strongly inhibit 
the proliferation of M12 cells. Majority of the compounds had a strong anti-proliferative 
activity in the M12 cell line, thus making it hard to distinguish a clear structure-activity 
relationship. There are several possible reasons for compounds showing different activity 
in different cell lines. Difference in the level of expression of CCR5 by each cell line 
could be an important factor. Also, different downstream signaling pathways could affect 
the activity of the antagonist. Compound 19 showed the best activity in the calcium 
mobilization assay. From the data, it could be inferred that this compound had the greatest 
ability in inhibiting the RANTES stimulated increase in intracellular calcium.   
In summary, a clear structure-activity relationship could not be established due to 
the limited number of compounds synthesized in this series. However, these studies are a 
beginning of a thorough analysis of the CCR5 antagonist binding pocket in the CCR5 
receptor. Further optimization of the structure could lead to development of the next 
generation of CCR5 antagonists. 
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